24. Literaturverzeichnis – Prävention Zervixkarzinom

1. Robert-Koch-Institut, http://www.rki.de/GBE/KREBS/KREBS.HTM, 2010., http://www.rki.de/gbe/krebs/krebs.htm

2. Soergel, P., Hillemanns, P., Die Versorgung von Zervixdysplasien mittels Konisationen in Deutschland, FRAUENARZT, 2011. 52(3): p. 210-215.

3. Burchell, A. N., Winer, R. L., de Sanjose, S., Franco, E. L., Chapter 6: Epidemiology and transmission dynamics of genital HPV infection, Vaccine, 2006. 24 Suppl 3(S3/52-S3/61): p. S3/52-61., https://www.ncbi.nlm.nih.gov/pubmed/16950018

4. Balshem, H., Helfand, M., Schunemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., et.al. GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 2011. 64(4): p. 401-6., https://www.ncbi.nlm.nih.gov/pubmed/21208779

5. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) - Ständige Kommission Leitlinien, AWMF-Regelwerk „Leitlinien“, 2012., http://www.awmf.org/leitlinien/awmf-regelwerk.html

6. Gemeinsamer Bundesausschuss, Beschluss über eine Änderung der Beauftragung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen: zur Erstellung von Einladungsschreiben und Versicherteninformation zum ZervixkarzinomscreeningGemeinsamer Bundesausschuss,, 2016., https://www.g-ba.de/downloads/39-261-2713/2016-09-15_Aenderung_Beauftragung-IQWiG_Einladung_Zervixkarzinom-Screening_vom-2015-03-19.pdf

7. Walboomers, Jan M. M., Jacobs, Marcel V., Manos, M. Michele, Bosch, F. Xavier, Kummer, J. Alain, Shah, Keerti V., et.al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, The Journal of Pathology, 1999. 189(1): p. 12-19., , to, ISI>://WOS:000082360300003

8. IARC, A Review of Human Carcinogens - Biological Agents, in IARC Monogr Eval Carcinog Risks Hum, 2012. 100B: p. 255-313.

9. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V., et.al. Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med, 2003. 348(6): p. 518-27., https://www.ncbi.nlm.nih.gov/pubmed/12571259

10. Schiffman, M., Clifford, G., Buonaguro, F. M., Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline, Infect Agent Cancer, 2009. 4: p. 8., https://www.ncbi.nlm.nih.gov/pubmed/19486508

11. Bzhalava, D., Guan, P., Franceschi, S., Dillner, J., Clifford, G., A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types, Virology, 2013. 445(1-2): p. 224-31., https://www.ncbi.nlm.nih.gov/pubmed/23928291

12. de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U., zur Hausen, H., Classification of papillomaviruses, Virology, 2004. 324(1): p. 17-27., https://www.ncbi.nlm.nih.gov/pubmed/15183049

13. Herfs, M., Yamamoto, Y., Laury, A., Wang, X., Nucci, M. R., McLaughlin-Drubin, M. E., et.al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer, Proc Natl Acad Sci U S A, 2012. 109(26): p. 10516-21., https://www.ncbi.nlm.nih.gov/pubmed/22689991

14. Doorbar, J., Quint, W., Banks, L., Bravo, I. G., Stoler, M., Broker, T. R., et.al. The biology and life-cycle of human papillomaviruses, Vaccine, 2012. 30 Suppl 5: p. F55-70., https://www.ncbi.nlm.nih.gov/pubmed/23199966

15. Maglennon, G. A., McIntosh, P., Doorbar, J., Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression, Virology, 2011. 414(2): p. 153-63., https://www.ncbi.nlm.nih.gov/pubmed/21492895

16. Briolat, J., Dalstein, V., Saunier, M., Joseph, K., Caudroy, S., Pretet, J. L., et.al. HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN, Int J Cancer, 2007. 121(10): p. 2198-204., https://www.ncbi.nlm.nih.gov/pubmed/17657742

17. Li, W., Wang, W., Si, M., Han, L., Gao, Q., Luo, A., et.al. The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma, J Cancer Res Clin Oncol, 2008. 134(12): p. 1355-61., https://www.ncbi.nlm.nih.gov/pubmed/18478264

18. Desaintes, C., Demeret, C., Goyat, S., Yaniv, M., Thierry, F., Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis, EMBO J, 1997. 16(3): p. 504-14., https://www.ncbi.nlm.nih.gov/pubmed/9034333

19. Stubenrauch, F., Straub, E., Fertey, J., Iftner, T., The E8 repression domain can replace the E2 transactivation domain for growth inhibition of HeLa cells by papillomavirus E2 proteins, Int J Cancer, 2007. 121(10): p. 2284-92., https://www.ncbi.nlm.nih.gov/pubmed/17583574

20. Wentzensen, N., Rodriguez, A. C., Viscidi, R., Herrero, R., Hildesheim, A., Ghosh, A., et.al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study, J Infect Dis, 2011. 204(1): p. 94-102., https://www.ncbi.nlm.nih.gov/pubmed/21628663

21. Iftner, T., HPV und Zervixkarzinom - Diagnostik und ProphylaxeUni-Med, 2008.

22. Stoler, M., Bergeron, C., Colgan, T.J., Ferenczy, A.S., Herrington, C.S., Kim, K.-R., et.al. Squamous cell tumours and precursors, in WHO Classification of Tumours of the Female Reproductive Organs, 2014, IARC.

23. Wilbur, D.C., Colgan, T.J., Ferenczy, A.S., Hirschowitz, L., Loening, T., McCluggage, W.G., et.al. Glandular tumours and precursors, in WHO Classification of Tumours of the Female Reproductive Organs, 2014, IARC.

24. Ostor, A. G., Natural history of cervical intraepithelial neoplasia: a critical review, Int J Gynecol Pathol, 1993. 12(2): p. 186-92., https://www.ncbi.nlm.nih.gov/pubmed/8463044

25. Globocan, 2012.

26. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W., Comber, H., et.al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 2013. 49(6): p. 1374-403., https://www.ncbi.nlm.nih.gov/pubmed/23485231

27. Arbyn, M., Castellsague, X., de Sanjose, S., Bruni, L., Saraiya, M., Bray, F., et.al. Worldwide burden of cervical cancer in 2008, Ann Oncol, 2011. 22(12): p. 2675-86., https://www.ncbi.nlm.nih.gov/pubmed/21471563

28. Eucan, Cervical cancer. Estimated incidence, mortality & prevalence, 2012., http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=25&Gender=2;, $http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=25&Gender=2$

29. Robert Koch Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Krebs in Deutschland 2009/2010, 2013. 9:

30. Gustafsson, L., Ponten, J., Bergstr”m, R., Adami, H. O., International incidence rates of invasive cervical cancer before cytological screening, International Journal of Cancer, 1997. 71(2): p. 159-165.

31. Becker, N., Epidemiological aspects of cancer screening in Germany, J Cancer Res Clin Oncol, 2003. 129(12): p. 691-702., https://www.ncbi.nlm.nih.gov/pubmed/14557878

32. Gesellschaft der Epidemiologischen Krebsregister in Deutschland e.V., Robert Koch-Institut, Krebs in Deutschland. Häufigkeiten und Trends, 2006. 5. aktualisierte Ausgabe:

33. Rositch, A. F., Nowak, R. G., Gravitt, P. E., Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009, Cancer, 2014. 120(13): p. 2032-8., https://www.ncbi.nlm.nih.gov/pubmed/24821088

34. Stang, A., Impact of hysterectomy on the age-specific incidence of cervical and uterine cancer in Germany and other countries, Eur J Public Health, 2013. 23(5): p. 879-83., https://www.ncbi.nlm.nih.gov/pubmed/22711786

35. Chen, T., Jansen, L., Gondos, A., Emrich, K., Holleczek, B., Luttmann, S., et.al. Survival of cervical cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage, Acta Oncol, 2012. 51(7): p. 915-21., https://www.ncbi.nlm.nih.gov/pubmed/22928692

36. Gondos, A., Arndt, V., Holleczek, B., Stegmaier, C., Ziegler, H., Brenner, H., Cancer survival in Germany and the United States at the beginning of the 21st century: An up-to-date comparison by period analysis, International Journal of Cancer, 2007. 19:, https://www.ncbi.nlm.nih.gov/pubmed/17372898

37. De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., et.al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study, Lancet Oncol, 2014. 15(1): p. 23-34., https://www.ncbi.nlm.nih.gov/pubmed/24314615

38. zur Hausen, H., Human papillomaviruses in the pathogenesis of anogenital cancer, Virology, 1991. 184(1): p. 9-13., https://www.ncbi.nlm.nih.gov/pubmed/1651607

39. Munoz, N., Bosch, F. X., de Sanjose, S., Tafur, L., Izarzugaza, I., Gili, M., et.al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain, International Journal of Cancer, 1992. 52(5): p. 743-749., https://www.ncbi.nlm.nih.gov/pubmed/1330933

40. Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., et.al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia, Journal of National Cancer Institute, 1993. 85(12): p. 958-964., https://www.ncbi.nlm.nih.gov/pubmed/8388478

41. Munoz, N., Bosch, F. X., The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer, Bull Pan Am Health Organ, 1996. 30(4): p. 362-377., https://www.ncbi.nlm.nih.gov/pubmed/9041748

42. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M., Shah, K. V., The casual relation between human papillomavirus and cervical cancer, Journal of clinical pathology, 2002. 55: p. 244-265., https://www.ncbi.nlm.nih.gov/pubmed/9041748

43. Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., Wacholder, S., Human papillomavirus and cervical cancer, Lancet, 2007. 370(9590): p. 890-907., https://www.ncbi.nlm.nih.gov/pubmed/17826171

44. Clifford, G., Franceschi, S., Diaz, M., Munoz, N., Villa, L. L., Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases, Vaccine, 2006. 24: p. S26-S34., https://www.ncbi.nlm.nih.gov/pubmed/16950015

45. Schiffman, M., Herrero, R., Desalle, R., Hildesheim, A., Wacholder, S., Rodriguez, A. C., et.al. The carcinogenicity of human papillomavirus types reflects viral evolution, Virology, 2005. 337(1): p. 76-84., https://www.ncbi.nlm.nih.gov/pubmed/15914222

46. Berkhof, J., Bulkmans, N. W., Bleeker, M. C., Bulk, S., Snijders, P. J., Voorhorst, F. J., et.al. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear, Cancer Epidemiol Biomarkers Prev, 2006. 15(7): p. 1268-73., https://www.ncbi.nlm.nih.gov/pubmed/16835322

47. Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M., Scott, D. R., et.al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst, 2005. 97(14): p. 1072-9., https://www.ncbi.nlm.nih.gov/pubmed/16030305

48. Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Hansson, B. G., et.al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study, Br J Cancer, 2007. 97(1): p. 129-32., https://www.ncbi.nlm.nih.gov/pubmed/17551490

49. 38383/PHS HHS/, Research Support, U.S. Gov't, P.H.S., J Infect Dis. 2005 Mar 1;191(5):731-8. doi: 10.1086/427557. Epub 2005 Jan 21., Winer, R. L., Kiviat, N. B., Hughes, J. P., et.al. Development and duration of human papillomavirus lesions, after initial infection, J Infect Dis, 2005. 191(5): p. 731-8., https://www.ncbi.nlm.nih.gov/pubmed/15688287

50. Kjaer, S. K., Frederiksen, K., Munk, C., Iftner, T., Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence, J Natl Cancer Inst, 2010. 102(19): p. 1478-88., https://www.ncbi.nlm.nih.gov/pubmed/20841605

51. Halec, G., Alemany, L., Lloveras, B., Schmitt, M., Alejo, M., Bosch, F. X., et.al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer, J Pathol, 2014. 234(4): p. 441-51., https://www.ncbi.nlm.nih.gov/pubmed/25043390

52. Gadducci, A., Barsotti, C., Cosio, S., Domenici, L., Riccardo, Genazzani A., Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature, Gynecol.Endocrinol., 2011. 27(8): p. 597-604., https://www.ncbi.nlm.nih.gov/pubmed/21438669

53. Plummer, M., Herrero, R., Franceschi, S., Meijer, C. J., Snijders, P., Bosch, F. X., et.al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study, Cancer Causes Control, 2003. 14(9): p. 805-14., https://www.ncbi.nlm.nih.gov/pubmed/14682438

54. Castellsague, X., Munoz, N., Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking, J Natl Cancer Inst Monogr, 2003. 31(31): p. 20-8., https://www.ncbi.nlm.nih.gov/pubmed/12807941

55. International Collaboration of Epidemiological Studies of, Cervical Cancer, Appleby, P., Beral, V., Berrington, de Gonzalez, Colin, D., Franceschi, S., et.al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies, The Lancet, 2007. 370(9599): p. 1609-1621., https://www.ncbi.nlm.nih.gov/pubmed/17993361

56. Insinga, R. P., Glass, A. G., Rush, B. B., Diagnoses and outcomes in cervical cancer screening: a population-based study, Am J Obstet Gynecol, 2004. 191(1): p. 105-13., https://www.ncbi.nlm.nih.gov/pubmed/15295350

57. Peto, J., Gilham, C., Deacon, J., Taylor, C., Evans, C., Binns, W., et.al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort, Br J Cancer, 2004. 91(5): p. 942-53., https://www.ncbi.nlm.nih.gov/pubmed/15292939

58. Marquardt, K., Broschewitz, U., Buttner, H. H., Barten, M., Zervixkarzinom trotz Früherkennungsprogramm, Frauenarzt, 2007. 48(11): p. 1086-1088.

59. Marquardt, K., Kolankowska, I., Pfandzetter, R., Jahresstatistik Zervix-Zytologie, Frauenarzt, 2014. 55(8): p. 732-3.

60. Grainge, M. J., Seth, R., Guo, L., Neal, K. R., Coupland, C., Vryenhoef, P., et.al. Cervical human papillomavirus screening among older women, Emerg Infect Dis, 2005. 11(11): p. 1680-5., https://www.ncbi.nlm.nih.gov/pubmed/16318718

61. Schiffman, M., Burk, R. D., Boyle, S., Raine-Bennett, T., Katki, H. A., Gage, J. C., et.al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results, J Clin Microbiol, 2015. 53(1): p. 52-9., https://www.ncbi.nlm.nih.gov/pubmed/25339396

62. Tjalma, W. A., Fiander, A., Reich, O., Powell, N., Nowakowski, A. M., Kirschner, B., et.al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe, Int J Cancer, 2013. 132(4): p. 854-67., https://www.ncbi.nlm.nih.gov/pubmed/22752992

63. Bruni, L., Diaz, M., Castellsague, X., Ferrer, E., Bosch, F. X., de Sanjose, S., Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings, J Infect Dis, 2010. 202(12): p. 1789-99., https://www.ncbi.nlm.nih.gov/pubmed/21067372

64. de Sanjose, S., Diaz, M., Castellsague, X., Clifford, G., Bruni, L., Munoz, N., et.al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis, Lancet Infect Dis, 2007. 7(7): p. 453-9., https://www.ncbi.nlm.nih.gov/pubmed/17597569

65. Bosch, F. X., Burchell, A. N., Schiffman, M., Giuliano, A. R., de Sanjose, S., Bruni, L., et.al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia, Vaccine, 2008. 26 Suppl 10: p. K1-16., https://www.ncbi.nlm.nih.gov/pubmed/18847553

66. De Vuyst, H., Clifford, G., Li, N., Franceschi, S., HPV infection in Europe, Eur J Cancer, 2009. 45(15): p. 2632-9., https://www.ncbi.nlm.nih.gov/pubmed/19709878

67. Smith, J. S., Melendy, A., Rana, R. K., Pimenta, J. M., Age-specific prevalence of infection with human papillomavirus in females: a global review, J Adolesc Health, 2008. 43(4 Suppl): p. S5-25, S25 e1-41., https://www.ncbi.nlm.nih.gov/pubmed/18809145

68. Dunne, E. F., Unger, E. R., Sternberg, M., McQuillan, G., Swan, D. C., Patel, S. S., et.al. Prevalence of HPV infection among females in the United States, JAMA, 2007. 297(8): p. 813-819., https://www.ncbi.nlm.nih.gov/pubmed/17327523

69. Hariri, S., Unger, E. R., Sternberg, M., Dunne, E. F., Swan, D., Patel, S., et.al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006, J Infect.Dis., 2011. 204(4): p. 566-573., https://www.ncbi.nlm.nih.gov/pubmed/21791659

70. Herrero, R., Hildesheim, A., Bratti, C., Sherman, M. E., Hutchinson, M., Morales, J., et.al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica, J Natl Cancer Inst, 2000. 92(6): p. 464-74., https://www.ncbi.nlm.nih.gov/pubmed/10716964

71. Trottier, H., Franco, E. L., The epidemiology of genital human papillomavirus infection, Vaccine, 2006. 24 Suppl 1: p. S1-15., https://www.ncbi.nlm.nih.gov/pubmed/16406226

72. Schneider, A., Screening for high grade cervical intraepithelial neoplasia and cancer by testing for high risk HPV, routine cytology or colposcopy, International Journal of Cancer, 2000. 89(6): p. 529-534., https://www.ncbi.nlm.nih.gov/pubmed/11102899

73. Petry, K. U., Menton, S., Menton, M., van Loenen-Frosch, F., de Carvalho Gomes, H., Holz, B., et.al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients, Br J Cancer, 2003. 88(10): p. 1570-7., https://www.ncbi.nlm.nih.gov/pubmed/12771924

74. Radde, K., Gottschalk, A., Bussas, U., Schulein, S., Schriefer, D., Seifert, U., et.al. Invitation to cervical cancer screening does increase participation in Germany: Results from the MARZY study, Int J Cancer, 2016. 139(5): p. 1018-30., https://www.ncbi.nlm.nih.gov/pubmed/27083776

75. Klug, S. J., Hukelmann, M., Hollwitz, B., Duzenli, N., Schopp, B., Petry, K. U., et.al. Prevalence of human papillomavirus types in women screened by cytology in Germany, J Med Virol, 2007. 79(5): p. 616-25., https://www.ncbi.nlm.nih.gov/pubmed/17385693

76. Iftner, T., Eberle, S., Iftner, A., Holz, B., Banik, N., Quint, W., et.al. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study, J.Med.Virol., 2010. 82(11): p. 1928-1939., https://www.ncbi.nlm.nih.gov/pubmed/20872721

77. Petry, K. U., Luyten, A., Justus, A., Iftner, A., Strehlke, S., Schulze-Rath, R., et.al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany, BMC Infect Dis, 2012. 12: p. 367., https://www.ncbi.nlm.nih.gov/pubmed/23259726

78. Delere, Y., Remschmidt, C., Leuschner, J., Schuster, M., Fesenfeld, M., Schneider, A., et.al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling, BMC Infect Dis, 2014. 14(1): p. 87., https://www.ncbi.nlm.nih.gov/pubmed/24552260

79. Winer, R. L., Lee, S. K., Hughes, J. P., Adam, D. E., Kiviat, N. B., Koutsky, L. A., Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students, Am J Epidemiol, 2003. 157(3): p. 218-26., https://www.ncbi.nlm.nih.gov/pubmed/12543621

80. Petry, K. U., Luyten, A., Justus, A., Iftner, A., Strehlke, S., Reinecke-Luthge, A., et.al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany, BMC Infect Dis, 2013. 13: p. 135., https://www.ncbi.nlm.nih.gov/pubmed/23497108

81. Palefsky, J. M., Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy, Curr Opin Oncol, 2003. 15(5): p. 382-8., https://www.ncbi.nlm.nih.gov/pubmed/12960521

82. Gross, G., et al., Impfprävention HPV-assoziierter Neoplasien, 2013., http://www.awmf.org/leitlinien/detail/ll/082-002.html

83. Koch-Institut, Robert, Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren - Empfehlung und Begründung., Epidemiologisches Bulletin. 2007, 2007. 12: p. 97-103.

84. Koch-Institut, Robert, Begründungen zu den aktuellen Empfehlungen vom Juli 2009: Bewertung der HPV-Impfung, Epidemiologisches Bulletin. 2009, 2009. 32: p. 319-328.

85. EMA, Gardasil, 2012., http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp.

86. EMA, Cervarix, 2012., http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124&murl=menus/medicines/medicines.jsp.

87. Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., et.al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases, N Engl J Med, 2007. 356(19): p. 1928-43., https://www.ncbi.nlm.nih.gov/pubmed/17494926

88. Apter, D., Wheeler, C. M., Paavonen, J., Castellsague, X., Garland, S. M., Skinner, S. R., et.al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial, Clin Vaccine Immunol, 2015. 22(4): p. 361-73., https://www.ncbi.nlm.nih.gov/pubmed/25651922

89. De Carvalho, N., Teixeira, J., Roteli-Martins, C. M., Naud, P., De Borba, P., Zahaf, T., et.al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women, Vaccine, 2010. 28(38): p. 6247-55., https://www.ncbi.nlm.nih.gov/pubmed/20643092

90. GlaxoSmithKline Vaccine, H. P. V. Study Group, Romanowski, B., de Borba, P. C., Naud, P. S., Roteli-Martins, C. M., De Carvalho, N. S., et.al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, Lancet, 2009. 374(9706): p. 1975-85., https://www.ncbi.nlm.nih.gov/pubmed/19962185

91. Kreimer, A. R., Struyf, F., Del Rosario-Raymundo, M. R., Hildesheim, A., Skinner, S. R., Wacholder, S., et.al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials, Lancet Oncol, 2015. 16(7): p. 775-86., https://www.ncbi.nlm.nih.gov/pubmed/26071347

92. Lehtinen, M., Paavonen, J., Wheeler, C. M., Jaisamrarn, U., Garland, S. M., Castellsague, X., et.al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, Lancet Oncol, 2012. 13(1): p. 89-99., https://www.ncbi.nlm.nih.gov/pubmed/22075171

93. Medina, D. M., Valencia, A., de Velasquez, A., Huang, L. M., Prymula, R., Garcia-Sicilia, J., et.al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls, J Adolesc Health, 2010. 46(5): p. 414-21., https://www.ncbi.nlm.nih.gov/pubmed/20413076

94. Paavonen, J., Naud, P., Salmeron, J., Wheeler, C. M., Chow, S. N., Apter, D., et.al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, Lancet, 2009. 374(9686): p. 301-14., https://www.ncbi.nlm.nih.gov/pubmed/19586656

95. Petaja, T., Pedersen, C., Poder, A., Strauss, G., Catteau, G., Thomas, F., et.al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women, Int J Cancer, 2011. 129(9): p. 2147-57., https://www.ncbi.nlm.nih.gov/pubmed/21190190

96. Schwarz, T. F., Huang, L. M., Medina, D. M., Valencia, A., Lin, T. Y., Behre, U., et.al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years, J Adolesc Health, 2012. 50(2): p. 187-94., https://www.ncbi.nlm.nih.gov/pubmed/22265115

97. Schwarz, T. F., Spaczynski, M., Schneider, A., Wysocki, J., Galaj, A., Perona, P., et.al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years, Vaccine, 2009. 27(4): p. 581-7., https://www.ncbi.nlm.nih.gov/pubmed/19022320

98. Szarewski, A., Poppe, W. A., Skinner, S. R., Wheeler, C. M., Paavonen, J., Naud, P., et.al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18, Int J Cancer, 2012. 131(1): p. 106-16., https://www.ncbi.nlm.nih.gov/pubmed/21858807

99. Szarewski, A., Skinner, S. R., Garland, S. M., Romanowski, B., Schwarz, T. F., Apter, D., et.al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation, J Infect Dis, 2013. 208(9): p. 1391-6., https://www.ncbi.nlm.nih.gov/pubmed/24092907

100. Wheeler, C. M., Castellsague, X., Garland, S. M., Szarewski, A., Paavonen, J., Naud, P., et.al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, Lancet Oncol, 2012. 13(1): p. 100-10., https://www.ncbi.nlm.nih.gov/pubmed/22075170

101. GlaxoSmithKline, Fachinformation Cervarix, 2013.

102. Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., et.al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet, 2004. 364(9447): p. 1757-65., https://www.ncbi.nlm.nih.gov/pubmed/15541448

103. Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., et.al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial, Lancet Oncol, 2005. 6(5): p. 271-8., https://www.ncbi.nlm.nih.gov/pubmed/15863374

104. Giuliano, A. R., Palefsky, J. M., Goldstone, S., Moreira, E. D., Jr., Penny, M. E., Aranda, C., et.al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males, N Engl J Med, 2011. 364(5): p. 401-11., https://www.ncbi.nlm.nih.gov/pubmed/21288094

105. Palefsky, J. M., Giuliano, A. R., Goldstone, S., Moreira, E. D., Jr., Aranda, C., Jessen, H., et.al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia, N Engl J Med, 2011. 365(17): p. 1576-85., https://www.ncbi.nlm.nih.gov/pubmed/22029979

106. Esposito, S., Birlutiu, V., Jarcuska, P., Perino, A., Man, S. C., Vladareanu, R., et.al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study, Pediatr Infect Dis J, 2011. 30(3): p. e49-55., https://www.ncbi.nlm.nih.gov/pubmed/21273939

107. Neuzil, K. M., Canh, D. G., Thiem, V. D., Janmohamed, A., Huong, V. M., Tang, Y., et.al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial, JAMA, 2011. 305(14): p. 1424-31., https://www.ncbi.nlm.nih.gov/pubmed/21486975

108. Zimmerman, R. K., Nowalk, M. P., Lin, C. J., Fox, D. E., Ko, F. S., Wettick, E., et.al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women, J Womens Health (Larchmt), 2010. 19(8): p. 1441-7., https://www.ncbi.nlm.nih.gov/pubmed/20629576

109. Joura, E. A., Garland, S. M., Paavonen, J., Ferris, D. G., Perez, G., Ault, K. A., et.al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data, BMJ, 2012. 344: p. e1401., https://www.ncbi.nlm.nih.gov/pubmed/22454089

110. Garland, S., et al., Does the HPV-16/18 AS04-adjuvanted vaccine benefit women with cervical disease?, Eurogin, 2011.

111. Kang, W. D., Choi, H. S., Kim, S. M., Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?, Gynecol Oncol, 2013. 130(2): p. 264-8., https://www.ncbi.nlm.nih.gov/pubmed/23623831

112. Hildesheim, A., Gonzalez, P., Kreimer, A. R., Wacholder, S., Schussler, J., Rodriguez, A. C., et.al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment, Am J Obstet Gynecol, 2016. 215(2): p. 212 e1-212 e15., https://www.ncbi.nlm.nih.gov/pubmed/26892991

113. Roteli-Martins, C. M., Naud, P., De Borba, P., Teixeira, J. C., De Carvalho, N. S., Zahaf, T., et.al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up, Hum Vaccin Immunother, 2012. 8(3): p. 390-7., https://www.ncbi.nlm.nih.gov/pubmed/22327492

114. Gee, J., Naleway, A., Shui, I., Baggs, J., Yin, R., Li, R., et.al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink, Vaccine, 2011. 29(46): p. 8279-84., https://www.ncbi.nlm.nih.gov/pubmed/21907257

115. Arnheim-Dahlstrom, L., Pasternak, B., Svanstrom, H., Sparen, P., Hviid, A., Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study, BMJ, 2013. 347: p. f5906., https://www.ncbi.nlm.nih.gov/pubmed/24108159

116. Giroglou, T., Sapp, M., Lane, C., Fligge, C., Christensen, N. D., Streeck, R. E., et.al. Immunological analyses of human papillomavirus capsids, Vaccine, 2001. 19(13-14): p. 1783-93., https://www.ncbi.nlm.nih.gov/pubmed/11166904

117. Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A. B., Romanowski, B., Roteli-Martins, C. M., et.al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, Lancet, 2006. 367(9518): p. 1247-55., https://www.ncbi.nlm.nih.gov/pubmed/16631880

118. Smith, J. F., Brownlow, M., Brown, M., Kowalski, R., Esser, M. T., Ruiz, W., et.al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions, Hum Vaccin, 2007. 3(4): p. 109-15., https://www.ncbi.nlm.nih.gov/pubmed/17611417

119. Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmeron, J., Wheeler, C. M., et.al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial, Lancet, 2007. 369(9580): p. 2161-2170., https://www.ncbi.nlm.nih.gov/pubmed/17602732

120. Ali, H., Guy, R. J., Wand, H., Read, T. R., Regan, D. G., Grulich, A. E., et.al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program, BMC Infect Dis, 2013. 13: p. 140., https://www.ncbi.nlm.nih.gov/pubmed/23506489

121. Donovan, B., Franklin, N., Guy, R., Grulich, A. E., Regan, D. G., Ali, H., et.al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data, Lancet Infect Dis, 2011. 11(1): p. 39-44., https://www.ncbi.nlm.nih.gov/pubmed/21067976

122. Fairley, C. K., Hocking, J. S., Gurrin, L. C., Chen, M. Y., Donovan, B., Bradshaw, C. S., Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women, Sex Transm Infect, 2009. 85(7): p. 499-502., https://www.ncbi.nlm.nih.gov/pubmed/19837728

123. Read, T. R., Hocking, J. S., Chen, M. Y., Donovan, B., Bradshaw, C. S., Fairley, C. K., The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme, Sex Transm Infect, 2011. 87(7): p. 544-7., https://www.ncbi.nlm.nih.gov/pubmed/21970896

124. Brotherton, J. M., Fridman, M., May, C. L., Chappell, G., Saville, A. M., Gertig, D. M., Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study, Lancet, 2011. 377(9783): p. 2085-92., https://www.ncbi.nlm.nih.gov/pubmed/21684381

125. Joura, E. A., Giuliano, A. R., Iversen, O. E., Bouchard, C., Mao, C., Mehlsen, J., et.al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women, N Engl J Med, 2015. 372(8): p. 711-23., https://www.ncbi.nlm.nih.gov/pubmed/25693011

126. Bos, A. B., van Ballegooijen, M., van den Akker-van Marle, M. E., Hanselaar, A. G., van Oortmarssen, G. J., Habbema, J. D., Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears, Am J Clin Pathol, 2001. 115(6): p. 851-5., https://www.ncbi.nlm.nih.gov/pubmed/11392881

127. Gemeinsamer Bundesausschuss, Beschlussbegründung Änderung der Richtlinien über die Früherkennung von Krebserkrankungen („Krebsfrüherkennungs-Richtlinien“)Gemeinsamer Bundesausschuss,, 2005. 2016:, https://www.g-ba.de/downloads/40-268-48/2005-07-19-Abstrich_Begruendung.pdf

128. McCrory, D. C., Matchar, D. B., Bastian, L., Datta, S., Hasselblad, V., Hickey, J., et.al. Evaluation of cervical cytology, Evid Rep Technol Assess (Summ), 1999. p. 1-6., https://www.ncbi.nlm.nih.gov/pubmed/11925972

129. Petry, K. U., Rinnau, F., Bohmer, G., Hollwitz, B., Luyten, A., Buttmann, N., et.al. Annual Papanicolaou screening for 5 years among human papillomavirus-negative women, BMC Cancer, 2013. 13: p. 379., https://www.ncbi.nlm.nih.gov/pubmed/23937771

130. Marquardt, K., Büttner, H.-H., Broschewitz, U., Barten, M., Die Restinzidenz des Zervixkarzinoms in Deutschland, Frauenarzt, 2004. 45(9): p. 812-815.

131. Schneider, A., Hoyer, H., Lotz, B., Leistritza, S., Kuhne-Heid, R., Nindl, I., et.al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy, Int J Cancer, 2000. 89(6): p. 529-34., https://www.ncbi.nlm.nih.gov/pubmed/11102899

132. Klug, S. J., Neis, K. J., Harlfinger, W., Malter, A., Konig, J., Spieth, S., et.al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance, Int J Cancer, 2013. 132(12): p. 2849-57., https://www.ncbi.nlm.nih.gov/pubmed/23175270

133. Ronco, G., Cuzick, J., Pierotti, P., Cariaggi, M. P., Dalla Palma, P., Naldoni, C., et.al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial, BMJ, 2007. 335(7609): p. 28., https://www.ncbi.nlm.nih.gov/pubmed/17517761

134. Siebers, A. G., Klinkhamer, P. J., Grefte, J. M., Massuger, L. F., Vedder, J. E., Beijers-Broos, A., et.al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial, JAMA, 2009. 302(16): p. 1757-64., https://www.ncbi.nlm.nih.gov/pubmed/19861667

135. Angstetra, D., Tait, T., Tan, J., Symonds, I., Should liquid-based cytology be performed prior to colposcopy? A comparison of the accuracy, unsatisfactory rates and cost in a tertiary referral setting, Aust N Z J Obstet Gynaecol, 2009. 49(6): p. 681-4., https://www.ncbi.nlm.nih.gov/pubmed/20070723

136. Bergeron, C., Bishop, J., Lemarie, A., Cas, F., Ayivi, J., Huynh, B., et.al. Accuracy of thin-layer cytology in patients undergoing cervical cone biopsy, Acta Cytol, 2001. 45(4): p. 519-24., https://www.ncbi.nlm.nih.gov/pubmed/11480712

137. Confortini, M., Bulgaresi, P., Cariaggi, M. P., Carozzi, F. M., Cecchini, S., Cipparrone, I., et.al. Comparing conventional and liquid-based smears from a consecutive series of 297 subjects referred to colposcopy assessment, Cytopathology, 2004. 15(3): p. 168-70., https://www.ncbi.nlm.nih.gov/pubmed/15165276

138. Confortini, M., Carozzi, F., Cortecchia, S., Macias, C. G., Sani, C., Tinacci, G., et.al. Technical evaluation of the new thin layer device CellSlide (Menarini Diagnostics), Diagn Cytopathol, 2005. 33(6): p. 387-93., https://www.ncbi.nlm.nih.gov/pubmed/16299751

139. Coste, J., Cochand-Priollet, B., de Cremoux, P., Le Gales, C., Cartier, I., Molinie, V., et.al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening, BMJ, 2003. 326(7392): p. 733., https://www.ncbi.nlm.nih.gov/pubmed/12676841

140. Ferenczy, A., Franco, E., Arseneau, J., Wright, T. C., Richart, R. M., Diagnostic performance of Hybrid Capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study, Am J Obstet Gynecol, 1996. 175(3 Pt 1): p. 651-6., https://www.ncbi.nlm.nih.gov/pubmed/8828429

141. Hussein, T., Desai, M., Tomlinson, A., Kitchener, H. C., The comparative diagnostic accuracy of conventional and liquid-based cytology in a colposcopic setting, BJOG, 2005. 112(11): p. 1542-6., https://www.ncbi.nlm.nih.gov/pubmed/16225576

142. Jesdapatarakul, S., Tangjitgamol, S., Nguansangiam, S., Manusirivithaya, S., Liqui-Prep(R) versus conventional Papanicolaou smear to detect cervical cells abnormality by split-sample technique: a randomized double-blind controlled trial, Diagn Cytopathol, 2011. 39(1): p. 22-7., https://www.ncbi.nlm.nih.gov/pubmed/20063407

143. Longatto Filho, A., Pereira, S. M., Di Loreto, C., Utagawa, M. L., Makabe, S., Sakamoto Maeda, M. Y., et.al. DCS liquid-based system is more effective than conventional smears to diagnosis of cervical lesions: study in high-risk population with biopsy-based confirmation, Gynecol Oncol, 2005. 97(2): p. 497-500., https://www.ncbi.nlm.nih.gov/pubmed/15863150

144. Sykes, P. H., Harker, D. Y., Miller, A., Whitehead, M., Neal, H., Wells, J. E., et.al. A randomised comparison of SurePath liquid-based cytology and conventional smear cytology in a colposcopy clinic setting, BJOG, 2008. 115(11): p. 1375-81., https://www.ncbi.nlm.nih.gov/pubmed/18823488

145. Taylor, S., Kuhn, L., Dupree, W., Denny, L., De Souza, M., Wright, T. C., Jr., Direct comparison of liquid-based and conventional cytology in a South African screening trial, Int J Cancer, 2006. 118(4): p. 957-62., https://www.ncbi.nlm.nih.gov/pubmed/16152600

146. Strander, B., Andersson-Ellstrom, A., Milsom, I., Radberg, T., Ryd, W., Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program : a prospective randomized study, Cancer, 2007. 111(5): p. 285-91., https://www.ncbi.nlm.nih.gov/pubmed/17724676

147. Joseph, M. G., Cragg, F., Wright, V. C., Kontozoglou, T. E., Downing, P., Marks, F. R., Cyto-histological correlates in a colposcopic clinic: a 1-year prospective study, Diagn Cytopathol, 1991. 7(5): p. 477-81., https://www.ncbi.nlm.nih.gov/pubmed/1954825

148. McCrory, D., Matchar, D., Bastian, L., Ahcpr, Miller, F., Nagel, L., et.al. Evaluation of cervical cytology, Evidence ReportTechnology Assessment No 5 No Agency for Health Care Policy and Research RockvilleMD USA Implementation of the ThinPrep Imaging System in a HighVolume Metropolitan Laboratory Diagn Cytopathol 213217, 2007. 35 SRC - GoogleScholar: p. 99-E010., https://www.ncbi.nlm.nih.gov/pubmed/11925972

149. Barroeta, J. E., Reilly, M. E., Steinhoff, M. M., Lawrence, W. D., Bibbo, M., Hawthorne, C., Utility of the Thin Prep Imaging System® in the detection of squamous intraepithelial abnormalities on retrospective evaluation: Can we trust the imager? Diagn Cytopathol, Nov 2 Epub ahead of print Performance of the AutoPap Primary Screening System at Jefferson University Hospital Acta Cytol, 1999. 43 SRC - GoogleScholar: p. 27-29.

150. Passamonti, B., Bulletti, S., Camilli, M., D'Amico, M. R., Di Dato, E., Gustinucci, D., et.al. Evaluation of the FocalPoint GS system performance in an Italian population-based screening of cervical abnormalities, Acta Cytol, 2007. 51(6): p. 865-71., https://www.ncbi.nlm.nih.gov/pubmed/18077978

151. Stein, Maira Degiovani, Performance and reproducibility of gynecologic cytology interpretation using the FocalPoint system: results of the RODEO Study Team, American journal of clinical pathology, 2013. 140(4): p. 567-71., https://www.ncbi.nlm.nih.gov/pubmed/24045555

152. Alasio, L. M., Alphandery, C., Grassi, P., Ruggeri, M., De Palo, G., Pilotti, S., Performance of the AutoPap Primary Screening System in the detection of high-risk cases in cervicovaginal smears, Acta Cytol, 2001. 45(5): p. 704-8., https://www.ncbi.nlm.nih.gov/pubmed/11575647

153. Vassilakos, Pierre, Use of automated primary screening on liquid-based, thin-layer preparations, Acta cytologica, 2002. 46(2): p. 291-5., https://www.karger.com/Article/Abstract/326724

154. Parker, Elizabeth M., FocalPoint slide classification algorithms show robust performance in classification of high-grade lesions on SurePath liquid-based cervical cytology slides, Diagnostic cytopathology, 2004. 30(2): p. 107-10., https://www.ncbi.nlm.nih.gov/pubmed/14755762

155. Troni, Grazia Maria, Reliability of sparing Papanicolaou test conventional reading in cases reported as No Further Review at AutoPap-assisted cytological screening: survey of 30,658 cases with follow-up cytological screening, Cancer, 2007. 111(2): p. 93-8., https://www.ncbi.nlm.nih.gov/pubmed/17330271

156. Kitchener, H. C., Blanks, R., Dunn, G., Gunn, L., Desai, M., Albrow, R., et.al. Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial, Lancet Oncol, 2011. 12(1): p. 56-64., https://www.ncbi.nlm.nih.gov/pubmed/21146458

157. Wilbur, David C., The Becton Dickinson FocalPoint GS Imaging System: clinical trials demonstrate significantly improved sensitivity for the detection of important cervical lesions, American journal of clinical pathology, 2009. 132(5): p. 767-75., https://www.ncbi.nlm.nih.gov/pubmed/19846820

158. Bowditch, Ron C., Clarke, Joanne M., Baird, Phillip J., Greenberg, Merle L., Results of an Australian trial using SurePath liquid-based cervical cytology with FocalPoint computer-assisted screening technology, Diagnostic cytopathology, 2012. 40(12): p. 1093-9., https://www.ncbi.nlm.nih.gov/pubmed/22045553

159. Chute, D. J., Lim, H., Kong, C. S., BD focalpoint slide profiler performance with atypical glandular cells on SurePath Papanicolaou smears, Cancer Cytopathol, 2010. 118(2): p. 68-74., https://www.ncbi.nlm.nih.gov/pubmed/20209621

160. Rowe, L. R., Marshall, C. J., Berry, M., Larson, M. A., Bentz, J. S., Accuracy of a slide profiler for endocervical cell detection in no-further-review conventional Pap smears, Acta Cytol, 2003. 47(4): p. 602-4., https://www.ncbi.nlm.nih.gov/pubmed/12920753

161. Wilbur, David C., Parker, Elizabeth M., Foti, Joseph A., Location-guided screening of liquid-based cervical cytology specimens: a potential improvement in accuracy and productivity is demonstrated in a preclinical feasibility trial, American journal of clinical pathology, 2002. 118(3): p. 399-407., https://www.ncbi.nlm.nih.gov/pubmed/12219782

162. Confortini, Massimo, A feasibility study of the use of the AutoPap screening system as a primary screening and location-guided rescreening device, Cancer, 2003. 99(3): p. 129-34., https://www.ncbi.nlm.nih.gov/pubmed/12811852

163. Ronco, Guglielmo, Impact of the AutoPap (currently Focalpoint) primary screening system location guide use on interpretation time and diagnosis, Cancer, 2003. 99(2): p. 83-8., https://www.ncbi.nlm.nih.gov/pubmed/12704687

164. Stevens, M. W., Milne, A. J., Parkinson, I. H., Nespolon, W. W., Fazzalari, N. L., Arora, N., et.al. Effectiveness of AutoPap system location-guided screening in the evaluation of cervical cytology smears, Diagn Cytopathol, 2004. 31(2): p. 94-9., https://www.ncbi.nlm.nih.gov/pubmed/15282720

165. Levi, A. W., Chhieng, D. C., Schofield, K., Kowalski, D., Harigopal, M., Implementation of FocalPoint GS location-guided imaging system: experience in a clinical setting, Cancer Cytopathol, 2012. 120(2): p. 126-33., https://www.ncbi.nlm.nih.gov/pubmed/22505211

166. Dziura, B., Quinn, S., Richard, K., Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the uterine cervix, Acta Cytol, 2006. 50(3): p. 309-11., https://www.ncbi.nlm.nih.gov/pubmed/16780026

167. Lozano, R., Comparison of computer-assisted and manual screening of cervical cytology, Gynecol Oncol, 2007. 104(1): p. 134-8., https://www.ncbi.nlm.nih.gov/pubmed/16959306

168. Chivukula, M., Saad, R. S., Elishaev, E., White, S., Mauser, N., Dabbs, D. J., Introduction of the Thin Prep Imaging System (TIS): experience in a high volume academic practice, Cytojournal, 2007. 4: p. 6., https://www.ncbi.nlm.nih.gov/pubmed/17288596

169. Miller, F. S., Nagel, L. E., Kenny-Moynihan, M. B., Implementation of the ThinPrep imaging system in a high-volume metropolitan laboratory, Diagn Cytopathol, 2007. 35(4): p. 213-7., https://www.ncbi.nlm.nih.gov/pubmed/17351933

170. Roberts, J. M., Thurloe, J. K., Bowditch, R. C., Hyne, S. G., Greenberg, M., Clarke, J. M., et.al. A three-armed trial of the ThinPrep Imaging System, Diagn Cytopathol, 2007. 35(2): p. 96-102., https://www.ncbi.nlm.nih.gov/pubmed/17230572

171. Davey, Elizabeth, Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study, BMJ (Clinical research ed.), 2007. 335(7609): p. 31., https://www.ncbi.nlm.nih.gov/pubmed/17604301

172. Papillo, J. L., St John, T. L., Leiman, G., Effectiveness of the ThinPrep Imaging System: clinical experience in a low risk screening population, Diagn Cytopathol, 2008. 36(3): p. 155-60., https://www.ncbi.nlm.nih.gov/pubmed/18232005

173. Pacheco, Maria Cristina, Concordance between original screening and final diagnosis using imager vs. manual screen of cervical liquid-based cytology slides, Acta cytologica, 2008. 52(5): p. 575-8., https://www.ncbi.nlm.nih.gov/pubmed/18833820

174. Duby, J. M., DiFurio, M. J., Implementation of the ThinPrep Imaging System in a tertiary military medical center, Cancer, 2009. 117(4): p. 264-70., https://www.ncbi.nlm.nih.gov/pubmed/19536887

175. Biscotti, Charles V., Assisted primary screening using the automated ThinPrep Imaging System, American journal of clinical pathology, 2005. 123(2): p. 281-7., https://www.ncbi.nlm.nih.gov/pubmed/15842055

176. Bolger, N., Heffron, C., Regan, I., Sweeney, M., Kinsella, S., McKeown, M., et.al. Implementation and evaluation of a new automated interactive image analysis system, Acta Cytol, 2006. 50(5): p. 483-91., https://www.ncbi.nlm.nih.gov/pubmed/17017432

177. Halford, J. A., Batty, T., Boost, T., Duhig, J., Hall, J., Lee, C., et.al. Comparison of the sensitivity of conventional cytology and the ThinPrep Imaging System for 1,083 biopsy confirmed high-grade squamous lesions, Diagn Cytopathol, 2010. 38(5): p. 318-26., https://www.ncbi.nlm.nih.gov/pubmed/19813268

178. Ha, S. Y., Lee, Y. K., Oh, Y. L., Effectiveness of the ThinPrep Imaging System in the detection of abnormal cervicovaginal cytology: a practical experience in Korea, Acta Cytol, 2013. 57(2): p. 159-63., https://www.ncbi.nlm.nih.gov/pubmed/23406895

179. Palmer, T. J., Nicoll, S. M., McKean, M. E., Park, A. J., Bishop, D., Baker, L., et.al. Prospective parallel randomized trial of the MultiCyte ThinPrep((R)) imaging system: the Scottish experience, Cytopathology, 2013. 24(4): p. 235-45., https://www.ncbi.nlm.nih.gov/pubmed/22616770

180. Friedlander, M. A., Rudomina, D., Lin, O., Effectiveness of the Thin Prep Imaging System in the detection of adenocarcinoma of the gynecologic system, Cancer, 2008. 114(1): p. 7-12., https://www.ncbi.nlm.nih.gov/pubmed/18085633

181. Kinney, W. K., Manos, M. M., Hurley, L. B., Ransley, J. E., Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses, Obstet Gynecol, 1998. 91(6): p. 973-6., https://www.ncbi.nlm.nih.gov/pubmed/9611007

182. Thrall, M. J., Russell, D. K., Bonfiglio, T. A., Hoda, R. S., Use of the ThinPrep Imaging System does not alter the frequency of interpreting Papanicolaou tests as atypical squamous cells of undetermined significance, Cytojournal, 2008. 5: p. 10., https://www.ncbi.nlm.nih.gov/pubmed/18435848

183. Quddus, M. Rudhul, Does the ThinPrep Imaging System increase the detection of high-risk HPV-positive ASC-US and AGUS? The Women and Infants Hospital experience with over 200,000 cervical cytology cases, CytoJournal, 2009. 6: p. 15., https://www.ncbi.nlm.nih.gov/pubmed/19826482

184. Zhao, C., Florea, A., Onisko, A., Austin, R. M., Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods, Gynecol Oncol, 2009. 114(3): p. 383-9., https://www.ncbi.nlm.nih.gov/pubmed/19501894

185. Sireci, A. N., Crapanzano, J. P., Mansukhani, M., Wright, T., Babiac, A., Erroll, M., et.al. Atypical glandular cells (AGC): ThinPrep Imaging System (TIS), manual screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing, Diagn Cytopathol, 2010. 38(10): p. 705-9., https://www.ncbi.nlm.nih.gov/pubmed/20014311

186. Wilbur, D. C., Detection of high grade squamous intraepithelial lesions and tumors using the AutoPap System: results of a primary screening clinical trial, Cancer, 1999. 87(6): p. 354-8., https://www.ncbi.nlm.nih.gov/pubmed/10603189

187. Schledermann, D., Hyldebrandt, T., Ejersbo, D., Hoelund, B., Automated screening versus manual screening: a comparison of the ThinPrep imaging system and manual screening in a time study, Diagn Cytopathol, 2007. 35(6): p. 348-52., https://www.ncbi.nlm.nih.gov/pubmed/17497655

188. Kitchener, H. C., Blanks, R., Cubie, H., Desai, M., Dunn, G., Legood, R., et.al. MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial, Health Technol Assess, 2011. 15(3): p. iii-iv, ix-xi, 1-170., https://www.ncbi.nlm.nih.gov/pubmed/21266159

189. Sweeney, Brenda J., Effects on cervical cytology screening productivity associated with implementation of the BD FocalPoint™ Guided Screener Imaging System, Acta cytologica, 2013. 57(2): p. 147-52., https://www.ncbi.nlm.nih.gov/pubmed/23406848

190. Elsheikh, Tarik M., Increasing cytotechnologist workload above 100 slides per day using the ThinPrep imaging system leads to significant reductions in screening accuracy, Cancer cytopathology, 2010. 118(2): p. 75-82., https://www.ncbi.nlm.nih.gov/pubmed/20151428

191. Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J., et.al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer, CA Cancer J.Clin., 2012. 62(3): p. 147-172., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801360/

192. Meijer, C. J., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., et.al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older, Int J Cancer, 2009. 124(3): p. 516-20., https://www.ncbi.nlm.nih.gov/pubmed/18973271

193. Stoler, M. H., Castle, P. E., Solomon, D., Schiffman, M., American Society for, Colposcopy, Cervical, Pathology, The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays, Am J Clin Pathol, 2007. 127(3): p. 335-7., https://www.ncbi.nlm.nih.gov/pubmed/17276947

194. Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., et.al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial, Lancet Oncol, 2010. 11(3): p. 249-57., https://www.ncbi.nlm.nih.gov/pubmed/20089449

195. Schiffman, M., Boyle, S., Raine-Bennett, T., Katki, H. A., Gage, J. C., Wentzensen, N., et.al. The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test, Cancer Epidemiol Biomarkers Prev, 2015. 24(9): p. 1304-10., https://www.ncbi.nlm.nih.gov/pubmed/26088703

196. Boers, A., Slagter-Menkema, L., van Hemel, B. M., Belinson, J. L., Ruitenbeek, T., Buikema, H. J., et.al. Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off, PLoS One, 2014. 9(7): p. e101930., https://www.ncbi.nlm.nih.gov/pubmed/25051098

197. Boehmer, G., Wang, L., Iftner, A., Holz, B., Haedicke, J., von Wasielewski, R., et.al. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off, BMC Infect Dis, 2014. 14: p. 674., https://www.ncbi.nlm.nih.gov/pubmed/25487281

198. Reid, J. L., Wright, T. C., Jr., Stoler, M. H., Cuzick, J., Castle, P. E., Dockter, J., et.al. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study, Am J Clin Pathol, 2015. 144(3): p. 473-83., https://www.ncbi.nlm.nih.gov/pubmed/26276778

199. Poljak, M., Ostrbenk, A., Seme, K., Sterbenc, A., Jancar, N., Vrtacnik Bokal, E., Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting, J Clin Virol, 2016. 76 Suppl 1: p. S29-S39., https://www.ncbi.nlm.nih.gov/pubmed/26643051

200. Arbyn, M., Snijders, P. J., Meijer, C. J., Berkhof, J., Cuschieri, K., Kocjan, B. J., et.al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?, Clin Microbiol Infect, 2015. 21(9): p. 817-26., https://www.ncbi.nlm.nih.gov/pubmed/25936581

201. Birnie, R., Wolff, R., Hilmer, D., Duffy, S., Kleijnen, J., Evidence Review for the S3 guideline “Prevention of Cervical Cancer”, 2014.

202. Kitchener, H. C., Almonte, M., Gilham, C., Dowie, R., Stoykova, B., Sargent, A., et.al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening, Health Technol Assess, 2009. 13(51): p. 1-150, iii-iv., https://www.ncbi.nlm.nih.gov/pubmed/19891902

203. Leinonen, M. K., Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland, BMJ (Clinical research ed.), 2012. 345: p. e7789., https://www.bmj.com/content/345/bmj.e7789

204. Rijkaart, D. C., Berkhof, J., Rozendaal, L., van Kemenade, F. J., Bulkmans, N. W., Heideman, D. A., et.al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial, Lancet Oncol, 2012. 13(1): p. 78-88., https://www.ncbi.nlm.nih.gov/pubmed/22177579

205. Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K., et.al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer, N Engl J Med, 2007. 357(16): p. 1589-97., https://www.ncbi.nlm.nih.gov/pubmed/17942872

206. Sankaranarayanan, R., Nene, B. M., Shastri, S. S., Jayant, K., Muwonge, R., Budukh, A. M., et.al. HPV screening for cervical cancer in rural India, N Engl J Med, 2009. 360(14): p. 1385-94., https://www.ncbi.nlm.nih.gov/pubmed/19339719

207. Kitchener, H. C., Almonte, M., Wheeler, P., Desai, M., Gilham, C., Bailey, A., et.al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial, Br J Cancer, 2006. 95(1): p. 56-61., https://www.ncbi.nlm.nih.gov/pubmed/16773068

208. Kitchener, H. C., Fletcher, I., Roberts, C., Wheeler, P., Almonte, M., Maguire, P., The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial, Int J Gynecol Cancer, 2008. 18(4): p. 743-8., https://www.ncbi.nlm.nih.gov/pubmed/17944916

209. Kitchener, H. C., Almonte, M., Thomson, C., Wheeler, P., Sargent, A., Stoykova, B., et.al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial, Lancet Oncol, 2009. 10(7): p. 672-82., https://www.ncbi.nlm.nih.gov/pubmed/19540162

210. Sargent, A., Bailey, A., Turner, A., Almonte, M., Gilham, C., Baysson, H., et.al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial, J Clin Microbiol, 2010. 48(2): p. 554-8., https://www.ncbi.nlm.nih.gov/pubmed/20007387

211. Kitchener, H. C., Gilham, C., Sargent, A., Bailey, A., Albrow, R., Roberts, C., et.al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial, Eur J Cancer, 2011. 47(6): p. 864-71., https://www.ncbi.nlm.nih.gov/pubmed/21334200

212. Anttila, A., Kotaniemi-Talonen, L., Leinonen, M., Hakama, M., Laurila, P., Tarkkanen, J., et.al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme, BMJ, 2010. 340(7754): p. c1804., https://www.ncbi.nlm.nih.gov/pubmed/20423964

213. Kotaniemi-Talonen, L., Nieminen, P., Anttila, A., Hakama, M., Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting, Br J Cancer, 2005. 93(8): p. 862-7., https://www.ncbi.nlm.nih.gov/pubmed/16189520

214. Kotaniemi-Talonen, L., Anttila, A., Malila, N., Tarkkanen, J., Laurila, P., Hakama, M., et.al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3, Eur J Cancer, 2008. 44(4): p. 565-71., https://www.ncbi.nlm.nih.gov/pubmed/18248809

215. Leinonen, M., Nieminen, P., Kotaniemi-Talonen, L., Malila, N., Tarkkanen, J., Laurila, P., et.al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting, J Natl Cancer Inst, 2009. 101(23): p. 1612-23., https://www.ncbi.nlm.nih.gov/pubmed/19903804

216. Malila, N., Leinonen, M., Kotaniemi-Talonen, L., Laurila, P., Tarkkanen, J., Hakama, M., The HPV test has similar sensitivity but more overdiagnosis than the Pap test--a randomised health services study on cervical cancer screening in Finland, Int J Cancer, 2013. 132(9): p. 2141-7., https://www.ncbi.nlm.nih.gov/pubmed/22987601

217. Giorgi-Rossi, P., Segnan, N., Zappa, M., Naldoni, C., Zorzi, M., Confortini, M., et.al. The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective, Int J Cancer, 2007. 121(12): p. 2729-34., https://www.ncbi.nlm.nih.gov/pubmed/17724715

218. Ronco, G., Segnan, N., Giorgi-Rossi, P., Zappa, M., Casadei, G. P., Carozzi, F., et.al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial, Journal of the National Cancer Institute, 2006. 98(11): p. 765-74., https://www.ncbi.nlm.nih.gov/pubmed/16757701

219. Ronco, G., Giorgi-Rossi, P., Carozzi, F., Dalla Palma, P., Del Mistro, A., De Marco, L., et.al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial, Lancet Oncol, 2006. 7(7): p. 547-55., https://www.ncbi.nlm.nih.gov/pubmed/16814206

220. Ronco, G., Cuzick, J., Segnan, N., Brezzi, S., Carozzi, F., Folicaldi, S., et.al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology, Eur J Cancer, 2007. 43(3): p. 476-80., https://www.ncbi.nlm.nih.gov/pubmed/17223540

221. Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., et.al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test, J Natl Cancer Inst, 2008. 100(7): p. 492-501., https://www.ncbi.nlm.nih.gov/pubmed/18364502

222. Budenholzer, B., Adding HPV testing to cytology screening reduced >= grade 3 cervical intraepithelial neoplasia at 5 years, Annals of Internal Medicine, 2012. 157(2): p. JC2-6., https://www.ncbi.nlm.nih.gov/pubmed/22801698

223. Bulkmans, N. W., Rozendaal, L., Snijders, P. J., Voorhorst, F. J., Boeke, A. J., Zandwijken, G. R., et.al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women, Int J Cancer, 2004. 110(1): p. 94-101., https://www.ncbi.nlm.nih.gov/pubmed/15054873

224. Bulkmans, N. W., Bulk, S., Ottevanger, M. S., Rozendaal, L., Hellenberg, S. M., van Kemenade, F. J., et.al. Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate, J Clin Pathol, 2006. 59(11): p. 1218-20., https://www.ncbi.nlm.nih.gov/pubmed/16943223

225. Bulkmans, N. W., Berkhof, J., Rozendaal, L., van Kemenade, F. J., Boeke, A. J., Bulk, S., et.al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial, Lancet, 2007. 370(9601): p. 1764-72., https://www.ncbi.nlm.nih.gov/pubmed/17919718

226. Sankaranarayanan, R., Nene, B. M., Dinshaw, K. A., Mahe, C., Jayant, K., Shastri, S. S., et.al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India, Int J Cancer, 2005. 116(4): p. 617-23., https://www.ncbi.nlm.nih.gov/pubmed/15818610

227. Elfgren, K., Rylander, E., Radberg, T., Strander, B., Strand, A., Paajanen, K., et.al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence, Am J Obstet Gynecol, 2005. 193(3 Pt 1): p. 650-7., https://www.ncbi.nlm.nih.gov/pubmed/16150255

228. Ronco, G., Dillner, J., Elfstrom, K. M., Tunesi, S., Snijders, P. J., Arbyn, M., et.al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials, Lancet, 2014. 383(9916): p. 524-32., https://www.ncbi.nlm.nih.gov/pubmed/24192252

229. Wu, R., Belinson, S. E., Du, H., Na, W., Qu, X., Wu, R., et.al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I, Int J Gynecol Cancer, 2010. 20(8): p. 1411-4., https://www.ncbi.nlm.nih.gov/pubmed/21051986

230. Ogilvie, G. S., van Niekerk, D. J., Krajden, M., Martin, R. E., Ehlen, T. G., Ceballos, K., et.al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial), BMC Cancer, 2010. 10: p. 111., https://www.ncbi.nlm.nih.gov/pubmed/20334685

231. Ogilvie, G. S., Krajden, M., van Niekerk, D. J., Martin, R. E., Ehlen, T. G., Ceballos, K., et.al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study, Br J Cancer, 2012. 107(12): p. 1917-24., https://www.ncbi.nlm.nih.gov/pubmed/23169286

232. Van Niekerk, D., Ogilvie, G., Krajden, M., Martin, R., Stuart, G., Ceballos, K., et.al. hrHPV DNA testing in cervical cancer screening. First round results From the HPV for CervicAL screening (HPV FOCAL) trial, Histopathology. Conference: 29th Congress of the International Academy of Pathology Cape Town South Africa. Conference Start: 20120930 Conference End: 20121005. Conference Publication: (var.pagings). 61 (pp 57), 2012. Date of Publication: October 2012., 2012.

233. Belinson, J. L., Wu, R., Belinson, S. E., Qu, X., Yang, B., Du, H., et.al. A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study, Am J Clin Pathol, 2011. 135(5): p. 790-5., https://www.ncbi.nlm.nih.gov/pubmed/21502436

234. Mayrand, M. H., Duarte-Franco, E., Coutlee, F., Rodrigues, I., Walter, S. D., Ratnam, S., et.al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST), Int J Cancer, 2006. 119(3): p. 615-23., https://www.ncbi.nlm.nih.gov/pubmed/16572425

235. Mayrand, M. H., Duarte-Franco, E., Rodrigues, I., Walter, S. D., Hanley, J., Ferenczy, A., et.al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer, N Engl J Med, 2007. 357(16): p. 1579-88., https://www.ncbi.nlm.nih.gov/pubmed/17942871

236. Cheng, J. X., Yao, L. L., Yuan, M., Liu, C. M., Guzhalinuer, Zhang, Y., HPV testing in diversion management of patients with ASCUS in cervical cytology. [Chinese], Journal of Practical Oncology, 2012. 27(6): p. 630-633., http://caod.oriprobe.com/articles/31218484/HPV_testing_in_diversion_management_of_patients_with_ASCUS_in_cervical.htm

237. Lazcano-Ponce, E., Lorincz, A. T., Cruz-Valdez, A., Salmeron, J., Uribe, P., Velasco-Mondragon, E., et.al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial, Lancet, 2011. 378(9806): p. 1868-73., https://www.ncbi.nlm.nih.gov/pubmed/22051739

238. Sancho-Garnier, H., Tamalet, C., Halfon, P., Leandri, F. X., Le Retraite, L., Djoufelkit, K., et.al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France, Int J Cancer, 2013. 133(11): p. 2681-7., https://www.ncbi.nlm.nih.gov/pubmed/23712523

239. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Nutzenbewertung eines HPV-Tests im Primärscreening des Zervixkarzinoms – Aktualisierung, IQWiG-Berichte, 2014. 222:

240. Alhamad, A., Al-Faris, E. A., The validation of the general health questionnaire (ghq-28) in a primary care setting in saudi arabia, J Family Community Med, 1998. 5(1): p. 13-9., https://www.ncbi.nlm.nih.gov/pubmed/23008578

241. Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA), GHQ-28, 2015., http://www.baua.de/de/Informationen-fuer-die-Praxis/Handlungshilfen-und-Praxisbeispiele/Toolbox/Verfahren/GHQ%2012.html

242. Luyten, A., Scherbring, S., Reinecke-Luthge, A., Braun, B. E., Pietralla, M., Theiler, K., et.al. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years, J Clin Virol, 2009. 46 Suppl 3: p. S5-10., https://www.ncbi.nlm.nih.gov/pubmed/20129072

243. Luyten, A., Buttmann-Schweiger, N., Luyten, K., Mauritz, C., Reinecke-Luthge, A., Pietralla, M., et.al. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme, Int J Cancer, 2014. 135(6): p. 1408-16., https://www.ncbi.nlm.nih.gov/pubmed/24519782

244. Arbyn, M., Ronco, G., Anttila, A., M. Meijer, C. J., Poljak, M., Ogilvie, G., et.al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer, Vaccine, 2012. 30(SUPPL.5): p. F88-F99., http://www.scopus.com/inward/record.url?eid=2-s2.0-84876558188&partnerID=40&md5=b517bce9742bec2af29528bd8cc31376

245. Liebrich, C., Brummer, O., Von Wasielewski, R., Wegener, G., Meijer, C., Iftner, T., et.al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents, Eur J Gynaecol Oncol, 2009. 30(1): p. 45-8., https://www.ncbi.nlm.nih.gov/pubmed/19317256

246. World Health Organization, WHO guidance note: comprehensive cervical cancer prevention and control: a healthier future for girls and women., 2013. 2015:, http://apps.who.int/iris/bitstream/10665/78128/3/9789241505147_eng.pdf?ua=1

247. IARC, Cervix Cancer ScreeningIARCPress, IARC Handbooks of Cancer Prevention, 2005. 10:

248. Gilham, C., Peto, J., Age at first smear and cervical cancer risk: recent UK incidence and mortality trends, HPV Infection and Related Cancers, EUROGIN 2015, 2015. p. 202., https://www.ncbi.nlm.nih.gov/pubmed/15262102

249. Sparen, P., Andrae, B., Benefit of cervical cancer screening in young women –a matter of adherence to the recommended screening interval., HPV Infection and Related Cancers, EUROGIN 2015, 2015. p. 201., https://www.bmj.com/content/339/bmj.b2968

250. Peirson, L., Fitzpatrick-Lewis, D., Ciliska, D., Warren, R., Screening for cervical cancer: a systematic review and meta-analysis, Syst Rev, 2013. 2: p. 35., https://www.ncbi.nlm.nih.gov/pubmed/23706117

251. Castle, P. E., Stoler, M. H., Wright, T. C., Jr., Sharma, A., Wright, T. L., Behrens, C. M., Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study, Lancet Oncol, 2011. 12(9): p. 880-90., https://www.ncbi.nlm.nih.gov/pubmed/21865084

252. Anttila, A., Ronco, G., Working Group on the, Registration, Monitoring of Cervical Cancer Screening Programmes in the European, Union, within the European Network for Information on, Cancer, Description of the national situation of cervical cancer screening in the member states of the European Union, Eur J Cancer, 2009. 45(15): p. 2685-708., https://www.ncbi.nlm.nih.gov/pubmed/19744852

253. Ikenberg, H., Zeitgemäße Zervixkarzinom-Vorsorge. Ein weltweites Thema, Diagnostik im Dialog, 2015. 46: p. 4-8.

254. Gage, J. C., Schiffman, M., Katki, H. A., Castle, P. E., Fetterman, B., Wentzensen, N., et.al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test, J Natl Cancer Inst, 2014. 106(8):, https://www.ncbi.nlm.nih.gov/pubmed/25038467

255. Dillner, J., Rebolj, M., Birembaut, P., Petry, K. U., Szarewski, A., Munk, C., et.al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study, BMJ, 2008. 337: p. a1754., https://www.ncbi.nlm.nih.gov/pubmed/18852164

256. Kinney, W., Wright, T. C., Dinkelspiel, H. E., DeFrancesco, M., Thomas Cox, J., Huh, W., Increased cervical cancer risk associated with screening at longer intervals, Obstet Gynecol, 2015. 125(2): p. 311-5., https://www.ncbi.nlm.nih.gov/pubmed/25568989

257. Andrae, B., Kemetli, L., Sparen, P., Silfverdal, L., Strander, B., Ryd, W., et.al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden, J Natl Cancer Inst, 2008. 100(9): p. 622-9., https://www.ncbi.nlm.nih.gov/pubmed/18445828

258. Lonnberg, S., Anttila, A., Luostarinen, T., Nieminen, P., Age-specific effectiveness of the Finnish cervical cancer screening programme, Cancer Epidemiol Biomarkers Prev, 2012. 21(8): p. 1354-61., https://www.ncbi.nlm.nih.gov/pubmed/22665576

259. Castanon, A., Landy, R., Brocklehurst, P., Evans, H., Peebles, D., Singh, N., et.al. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control studyPG-1208-16187/Department of Health/United Kingdom, BMJ, 2014. 349: p. g6223., https://www.ncbi.nlm.nih.gov/pubmed/25378384

260. Dinkelspiel, H., Fetterman, B., Poitras, N., Kinney, W., Cox, J. T., Lorey, T., et.al. Screening history preceding a diagnosis of cervical cancer in women age 65 and older, Gynecol Oncol, 2012. 126(2): p. 203-6., https://www.ncbi.nlm.nih.gov/pubmed/22561038

261. Geyer, S., Jaunzeme, J., Hillemanns, P., Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data, Arch Gynecol Obstet, 2015. 291(3): p. 623-9., https://www.ncbi.nlm.nih.gov/pubmed/25138124

262. Tabrizi, S. N., Brotherton, J. M., Kaldor, J. M., Skinner, S. R., Liu, B., Bateson, D., et.al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study, Lancet Infect Dis, 2014. 14(10): p. 958-66., https://www.ncbi.nlm.nih.gov/pubmed/25107680

263. Brotherton, J. M., Tabrizi, S. N., Garland, S. M., Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance, Future Microbiol, 2012. 7(2): p. 193-9., https://www.ncbi.nlm.nih.gov/pubmed/22324989

264. Stokes-Lampard, H., Wilson, S., Waddell, C., Ryan, A., Holder, R., Kehoe, S., Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature, BJOG, 2006. 113(12): p. 1354-65., https://www.ncbi.nlm.nih.gov/pubmed/17081187

265. Alemany, L., Saunier, M., Tinoco, L., Quiros, B., Alvarado-Cabrero, I., Alejo, M., et.al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples, Eur J Cancer, 2014. 50(16): p. 2846-54., https://www.ncbi.nlm.nih.gov/pubmed/25155250

266. Dugue, P. A., Rebolj, M., Garred, P., Lynge, E., Immunosuppression and risk of cervical cancer, Expert Rev Anticancer Ther, 2013. 13(1): p. 29-42., https://www.ncbi.nlm.nih.gov/pubmed/23259425

267. Maiman, M., Management of cervical neoplasia in human immunodeficiency virus-infected women, J Natl Cancer Inst Monogr, 1998. p. 43-9., https://www.ncbi.nlm.nih.gov/pubmed/9709302

268. Petry, K. U., Scheffel, D., Bode, U., Gabrysiak, T., Kochel, H., Kupsch, E., et.al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions, Int J Cancer, 1994. 57(6): p. 836-40., https://www.ncbi.nlm.nih.gov/pubmed/7911455

269. Petry, K. U., Kochel, H., Bode, U., Schedel, I., Niesert, S., Glaubitz, M., et.al. Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women, Gynecol Oncol, 1996. 60(1): p. 30-4., https://www.ncbi.nlm.nih.gov/pubmed/8557224

270. Arbyn, M., Roelens, J., Simoens, C., Buntinx, F., Paraskevaidis, E., Martin-Hirsch, P. P., et.al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions, Cochrane Database Syst Rev, 2013. 3(3): p. CD008054., https://www.ncbi.nlm.nih.gov/pubmed/23543559

271. Verdoodt, F., Szarewski, A., Halfon, P., Cuschieri, K., Arbyn, M., Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types, Cancer Cytopathol, 2013. 121(12): p. 675-87., https://www.ncbi.nlm.nih.gov/pubmed/23881840

272. Roelens, J., Reuschenbach, M., von Knebel Doeberitz, M., Wentzensen, N., Bergeron, C., Arbyn, M., p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis, Cancer Cytopathol, 2012. 120(5): p. 294-307., https://www.ncbi.nlm.nih.gov/pubmed/22700382

273. Solomon, D., Schiffman, M., Tarone, R., group, Alts Study, Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial, J Natl Cancer Inst, 2001. 93(4): p. 293-9., https://www.ncbi.nlm.nih.gov/pubmed/11181776

274. Balasubramanian, A., Hughes, J., Mao, C., Ridder, R., Herkert, M., Kiviat, N. B., et.al. Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer, Cancer Epidemiology Biomarkers and Prevention, 2009. 18(11): p. 3008-3017., http://www.scopus.com/inward/record.url?eid=2-s2.0-72749089630&partnerID=40&md5=190c41ac3ad28cd5395aa20f4212d19f

275. Hovland, S., Arbyn, M., Lie, A. K., Ryd, W., Borge, B., Berle, E. J., et.al. A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo, Br J Cancer, 2010. 102(6): p. 957-65., https://www.ncbi.nlm.nih.gov/pubmed/20197765

276. Depuydt, C. E., Makar, A. P., Ruymbeke, M. J., Benoy, I. H., Vereecken, A. J., Bogers, J. J., BD-ProExC as adjunct molecular marker for improved detection of CIN2 + after HPV primary screening, Cancer Epidemiology Biomarkers and Prevention, 2011. 20(4): p. 628-637., http://www.scopus.com/inward/record.url?eid=2-s2.0-79955783142&partnerID=40&md5=cc0a20d49d22f59f5167d217a62ccc9e

277. Monsonego, J., Hudgens, M. G., Zerat, L., Zerat, J. C., Syrjanen, K., Halfon, P., et.al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study, Int J Cancer, 2011. 129(3): p. 691-701., https://www.ncbi.nlm.nih.gov/pubmed/20941740

278. Ratnam, S., Coutlee, F., Fontaine, D., Bentley, J., Escott, N., Ghatage, P., et.al. Aptima HPV E6/E7 mRNA test is as sensitive as hybrid capture 2 assay but more specific at detecting cervical precancer and cancer, Journal of Clinical Microbiology, 2011. 49(2): p. 557-564., http://www.scopus.com/inward/record.url?eid=2-s2.0-79951474334&partnerID=40&md5=f3d8ccda3238c032d2a104f27e46f841

279. Cuzick, J., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Ho, L., et.al. Comparing the performance of six human papillomavirus tests in a screening population, Br J Cancer, 2013. 108(4): p. 908-13., https://www.ncbi.nlm.nih.gov/pubmed/23370211

280. Nieves, L., Enerson, C. L., Belinson, S., Brainard, J., Chiesa-Vottero, A., Nagore, N., et.al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection, International Journal of Gynecological Cancer, 2013. 23(3): p. 513-518., http://www.scopus.com/inward/record.url?eid=2-s2.0-84876243265&partnerID=40&md5=0e06c20425488ccaf159a1fe9d218bd5

281. Ikenberg, H., Bergeron, C., Schmidt, D., Griesser, H., Alameda, F., Angeloni, C., et.al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study, J Natl Cancer Inst, 2013. 105(20): p. 1550-7., https://www.ncbi.nlm.nih.gov/pubmed/24096620

282. Zhao, F. H., Jeronimo, J., Qiao, Y. L., Schweizer, J., Chen, W., Valdez, M., et.al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China, Cancer Prev Res (Phila), 2013. 6(9): p. 938-48., https://www.ncbi.nlm.nih.gov/pubmed/23878179

283. Whiting, P. F., Rutjes, A. W., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., et.al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, 2011. 155(8): p. 529-36., https://www.ncbi.nlm.nih.gov/pubmed/22007046

284. Wright, T. C., Jr., Cox, J. T., Massad, L. S., Twiggs, L. B., Wilkinson, E. J., Conference, A. SCCP-Sponsored Consensus, 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities, JAMA, 2002. 287(16): p. 2120-9., https://www.ncbi.nlm.nih.gov/pubmed/11966387

285. Jordan, J., Martin-Hirsch, P., Arbyn, M., Schenck, U., Baldauf, J. J., Da Silva, D., et.al. European guidelines for clinical management of abnormal cervical cytology, part 2, Cytopathology, 2009. 20(1): p. 5-16., https://www.ncbi.nlm.nih.gov/pubmed/19133067

286. Solomon, D., Davey, D., Kurman, R., Moriarty, A., O'Connor, D., Prey, M., et.al. The 2001 Bethesda System: terminology for reporting results of cervical cytology, JAMA, 2002. 287(16): p. 2114-9., https://www.ncbi.nlm.nih.gov/pubmed/11966386

287. Arbyn, M., Sasieni, P., Meijer, C. J., Clavel, C., Koliopoulos, G., Dillner, J., Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses, Vaccine, 2006. 24 Suppl 3(SUPPL. 3): p. S3/78-89., https://www.ncbi.nlm.nih.gov/pubmed/16950021

288. Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., et.al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive, J Low Genit Tract Dis, 2013. 17(5 Suppl 1): p. S56-63., https://www.ncbi.nlm.nih.gov/pubmed/23519306

289. Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., et.al. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results, J Low Genit Tract Dis, 2013. 17(5 Suppl 1): p. S36-42., https://www.ncbi.nlm.nih.gov/pubmed/23519303

290. Arbyn, Marc, Haelens, Annemie, Desomer, Anja, Verdoodt, Freija, Francart, Julie, Thiry, Nancy, et.al. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screeningBelgian Health Care Knowledge Centre (KCE), KCE Reports, 2015.

291. Wright, T. C., Jr., Behrens, C. M., Ranger-Moore, J., Rehm, S., Sharma, A., Stoler, M. H., et.al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial, Gynecol Oncol, 2017. 144(1): p. 51-56., https://www.ncbi.nlm.nih.gov/pubmed/28094038

292. Luyten, A., Petry, K. U., Relevance of HPV Screening for Triaging Equivocal Cytology Findings in the Pap II-p, Pap III and Pap IIID Groups - Results of Two Long-Term Studies, Geburtshilfe Frauenheilkd, 2015. 75(10): p. 1058-1062., https://www.ncbi.nlm.nih.gov/pubmed/26556908

293. Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., et.al. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results, J Low Genit Tract Dis, 2013. 17(5 Suppl 1): p. S43-9., https://www.ncbi.nlm.nih.gov/pubmed/23519304

294. Arbyn, M., Roelens, J., Cuschieri, K., Cuzick, J., Szarewski, A., Ratnam, S., et.al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy, Int J Cancer, 2013. 132(1): p. 101-8., https://www.ncbi.nlm.nih.gov/pubmed/22610699

295. Rijkaart, D. C., Berkhof, J., van Kemenade, F. J., Coupe, V. M., Hesselink, A. T., Rozendaal, L., et.al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening, Int J Cancer, 2012. 130(3): p. 602-10., https://www.ncbi.nlm.nih.gov/pubmed/21400507

296. Carozzi, Francesca, Confortini, Massimo, Palma, Paolo Dalla, Del Mistro, Annarosa, Gillio-Tos, Anna, De Marco, Laura, et.al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial, The Lancet Oncology, 2008. 9(10): p. 937-945., http://www.sciencedirect.com/science/article/pii/S1470204508702080

297. Carozzi, F., Gillio-Tos, A., Confortini, M., Del Mistro, A., Sani, C., De Marco, L., et.al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial, Lancet Oncol, 2013. 14(2): p. 168-76., https://www.ncbi.nlm.nih.gov/pubmed/23261355

298. Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K., et.al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening, J Natl Cancer Inst, 2009. 101(2): p. 88-99., https://www.ncbi.nlm.nih.gov/pubmed/19141778

299. Dijkstra, M. G., van Niekerk, D., Rijkaart, D. C., van Kemenade, F. J., Heideman, D. A., Snijders, P. J., et.al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy, Cancer Epidemiol Biomarkers Prev, 2014. 23(1): p. 55-63., https://www.ncbi.nlm.nih.gov/pubmed/23733907

300. Leinonen, M. K., Anttila, A., Malila, N., Dillner, J., Forslund, O., Nieminen, P., Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland, Br J Cancer, 2013. 109(11): p. 2941-50., https://www.ncbi.nlm.nih.gov/pubmed/24136148

301. Manos, M. M., Kinney, W. K., Hurley, L. B., Sherman, M. E., Shieh-Ngai, J., Kurman, R. J., et.al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results, JAMA, 1999. 281(17): p. 1605-10., https://www.ncbi.nlm.nih.gov/pubmed/10235153

302. Bergeron, C., Jeannel, D., Poveda, J., Cassonnet, P., Orth, G., Human papillomavirus testing in women with mild cytologic atypia, Obstet Gynecol, 2000. 95(6 Pt 1): p. 821-7., https://www.ncbi.nlm.nih.gov/pubmed/10831974

303. Lytwyn, A., Sellors, J. W., Mahony, J. B., Daya, D., Chapman, W., Ellis, N., et.al. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group, CMAJ, 2000. 163(6): p. 701-7., https://www.ncbi.nlm.nih.gov/pubmed/11022584

304. Shlay, J. C., Dunn, T., Byers, T., Baron, A. E., Douglas, J. M., Jr., Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears, Obstet Gynecol, 2000. 96(3): p. 410-6., https://www.ncbi.nlm.nih.gov/pubmed/10960635

305. Morin, C., Bairati, I., Bouchard, C., Fortier, M., Roy, M., Moore, L., et.al. Managing atypical squamous cells of undetermined significance in Papanicolaou smears, J Reprod Med, 2001. 46(9): p. 799-805., https://www.ncbi.nlm.nih.gov/pubmed/11584480

306. Rebello, G., Hallam, N., Smart, G., Farquharson, D., McCafferty, J., Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study, BMJ, 2001. 322(7291): p. 893-4., https://www.ncbi.nlm.nih.gov/pubmed/11302900

307. Kulasingam, S. L., Hughes, J. P., Kiviat, N. B., Mao, C., Weiss, N. S., Kuypers, J. M., et.al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral, JAMA, 2002. 288(14): p. 1749-57., https://www.ncbi.nlm.nih.gov/pubmed/12365959

308. Pretorius, R. G., Belinson, J. L., Burchette, R. J., Hu, S., Zhang, X., Qiao, Y. L., Regardless of skill, performing more biopsies increases the sensitivity of colposcopy, J Low Genit Tract Dis, 2011. 15(3): p. 180-8., https://www.ncbi.nlm.nih.gov/pubmed/21436729

309. Cuzick, J., Szarewski, A., Cubie, H., Hulman, G., Kitchener, H., Luesley, D., et.al. Management of women who test positive for high-risk types of human papillomavirus: the HART study, Lancet, 2003. 362(9399): p. 1871-6., https://www.ncbi.nlm.nih.gov/pubmed/14667741

310. Guyot, A., Karim, S., Kyi, M. S., Fox, J., Evaluation of adjunctive HPV testing by Hybrid Capture II in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy, BMC Infect Dis, 2003. 3: p. 23., https://www.ncbi.nlm.nih.gov/pubmed/14511396

311. Lonky, N. M., Felix, J. C., Naidu, Y. M., Wolde-Tsadik, G., Triage of atypical squamous cells of undetermined significance with hybrid capture II: colposcopy and histologic human papillomavirus correlation, Obstet Gynecol, 2003. 101(3): p. 481-9., https://www.ncbi.nlm.nih.gov/pubmed/12636951

312. Ordi, J., Puig-Tintore, L. M., Torne, A., Sanz, S., Esteve, R., Romagosa, C., et.al. [Contribution of high risk human papillomavirus testing to the management of premalignant and malignant lesions of the uterine cervix], Med Clin (Barc), 2003. 121(12): p. 441-5., https://www.ncbi.nlm.nih.gov/pubmed/14572367

313. Wensveen, C., Kagie, M., Veldhuizen, R., De Groot, C., Denny, L., Zwinderman, K., et.al. Detection of cervical intraepithelial neoplasia in women with atypical squamous or glandular cells of undetermined significance cytology: a prospective study, Acta Obstet Gynecol Scand, 2003. 82(9): p. 883-9., https://www.ncbi.nlm.nih.gov/pubmed/12911453

314. Andersson, S., Dillner, L., Elfgren, K., Mints, M., Persson, M., Rylander, E., A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities, Acta Obstet Gynecol Scand, 2005. 84(10): p. 996-1000., https://www.ncbi.nlm.nih.gov/pubmed/16167918

315. Dalla Palma, P., Pojer, A., Girlando, S., HPV triage of women with atypical squamous cells of undetermined significance: a 3-year experience in an Italian organized programme, Cytopathology, 2005. 16(1): p. 22-6., https://www.ncbi.nlm.nih.gov/pubmed/15859311

316. Davis-Devine, S., Day, S. J., Freund, G. G., Test performance comparison of inform HPV and hybrid capture 2 high-risk HPV DNA tests using the SurePath liquid-based Pap test as the collection method, Am J Clin Pathol, 2005. 124(1): p. 24-30., https://www.ncbi.nlm.nih.gov/pubmed/15923167

317. Giovannelli, L., Capra, G., Lama, A., Bustinto, T., Genco, A., Valenti, F. M., et.al. Atypical squamous cells of undetermined significance-favour reactive compared to atypical squamous cells of undetermined significance-favour dysplasia: association with cervical intraepithelial lesions and human papillomavirus infection, J Clin Virol, 2005. 33(4): p. 281-6., https://www.ncbi.nlm.nih.gov/pubmed/16036177

318. Nieh, S., Chen, S. F., Chu, T. Y., Lai, H. C., Lin, Y. S., Fu, E., et.al. Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies, Gynecol Oncol, 2005. 97(1): p. 35-40., https://www.ncbi.nlm.nih.gov/pubmed/15790434

319. Bergeron, C., Cas, F., Fagnani, F., Contrepas, A., Wadier, R., Poveda, J. D., [Assessment of human papillomavirus testing on liquid-based Cyto-screen system for women with atypical squamous cells of undetermined significance. Effect of age], Gynecol Obstet Fertil, 2006. 34(4): p. 312-6., https://www.ncbi.nlm.nih.gov/pubmed/16581283

320. Holladay, E. B., Logan, S., Arnold, J., Knesel, B., Smith, G. D., A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia, Cancer, 2006. 108(6): p. 451-61., https://www.ncbi.nlm.nih.gov/pubmed/17078096

321. Kelly, D., Kincaid, E., Fansler, Z., Rosenthal, D. L., Clark, D. P., Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx C), Cancer, 2006. 108(6): p. 494-500., https://www.ncbi.nlm.nih.gov/pubmed/17063495

322. Kiatpongsan, S., Niruthisard, S., Mutirangura, A., Trivijitsilp, P., Vasuratna, A., Chaithongwongwatthana, S., et.al. Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance, Int J Gynecol Cancer, 2006. 16(1): p. 262-5., https://www.ncbi.nlm.nih.gov/pubmed/16445642

323. Monsonego, J., Pintos, J., Semaille, C., Beumont, M., Dachez, R., Zerat, L., et.al. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia, Int J Gynecol Cancer, 2006. 16(2): p. 591-8., https://www.ncbi.nlm.nih.gov/pubmed/16681731

324. Ronco, G., Cuzick, J., Segnan, N., Brezzi, S., Carozzi, F., Folicaldi, S., et.al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology, Eur J Cancer, 2007. 43(3): p. 476-80., https://www.ncbi.nlm.nih.gov/pubmed/17223540

325. De Francesco, M. A., Gargiulo, F., Schreiber, C., Ciravolo, G., Salinaro, F., Manca, N., Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear, J Virol Methods, 2008. 147(1): p. 10-7., https://www.ncbi.nlm.nih.gov/pubmed/17854914

326. Monsonego, J., Pollini, G., Evrard, M. J., Sednaoui, P., Monfort, L., Zerat, L., et.al. Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests, Sex Transm Dis, 2008. 35(5): p. 521-7., https://www.ncbi.nlm.nih.gov/pubmed/18434944

327. Siddiqui, M. T., Hornaman, K., Cohen, C., Nassar, A., ProEx C immunocytochemistry and high-risk human papillomavirus DNA testing in papanicolaou tests with atypical squamous cell (ASC-US) cytology: correlation study with histologic biopsy, Arch Pathol Lab Med, 2008. 132(10): p. 1648-52., https://www.ncbi.nlm.nih.gov/pubmed/18834224

328. Szarewski, A., Ambroisine, L., Cadman, L., Austin, J., Ho, L., Terry, G., et.al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears, Cancer Epidemiol Biomarkers Prev, 2008. 17(11): p. 3033-42., https://www.ncbi.nlm.nih.gov/pubmed/18957520

329. Cattani, P., Zannoni, G. F., Ricci, C., D'Onghia, S., Trivellizzi, I. N., Di Franco, A., et.al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix, J Clin Microbiol, 2009. 47(12): p. 3895-901., https://www.ncbi.nlm.nih.gov/pubmed/19828739

330. Silverloo, I., Andrae, B., Wilander, E., Value of high-risk HPV-DNA testing in the triage of ASCUS, Acta Obstet Gynecol Scand, 2009. 88(9): p. 1006-10., https://www.ncbi.nlm.nih.gov/pubmed/19690991

331. Del Mistro, A., Frayle-Salamanca, H., Trevisan, R., Matteucci, M., Pinarello, A., Zambenedetti, P., et.al. Triage of women with atypical squamous cells of undetermined significance (ASC-US): results of an Italian multicentric study, Gynecol Oncol, 2010. 117(1): p. 77-81., https://www.ncbi.nlm.nih.gov/pubmed/20116836

332. Denton, K. J., Bergeron, C., Klement, P., Trunk, M. J., Keller, T., Ridder, R., et.al. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results, Am J Clin Pathol, 2010. 134(1): p. 12-21., https://www.ncbi.nlm.nih.gov/pubmed/20551261

333. Halfon, P., Benmoura, D., Agostini, A., Khiri, H., Penaranda, G., Martineau, A., et.al. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy, Cancer Biomark, 2010. 7(3): p. 133-9., https://www.ncbi.nlm.nih.gov/pubmed/21263189

334. Alameda, F., Pijuan, L., Lloveras, B., Bellosillo, B., Larrazabal, F., Mancebo, G., et.al. The value of p16 in ASCUS cases: a retrospective study using frozen cytologic material, Diagn Cytopathol, 2011. 39(2): p. 110-4., https://www.ncbi.nlm.nih.gov/pubmed/21254457

335. Clad, A., Reuschenbach, M., Weinschenk, J., Grote, R., Rahmsdorf, J., Freudenberg, N., Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology, J Clin Microbiol, 2011. 49(3): p. 1071-6., https://www.ncbi.nlm.nih.gov/pubmed/21191046

336. Dufresne, S., Sauthier, P., Mayrand, M. H., Petignat, P., Provencher, D., Drouin, P., et.al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with Amplicor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix, J Clin Microbiol, 2011. 49(1): p. 48-53., https://www.ncbi.nlm.nih.gov/pubmed/21084508

337. Monsonego, J., Hudgens, M. G., Zerat, L., Zerat, J. C., Syrjanen, K., Halfon, P., et.al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study, Int J Cancer, 2011. 129(3): p. 691-701., https://www.ncbi.nlm.nih.gov/pubmed/20941740

338. Schmidt, D., Bergeron, C., Denton, K. J., Ridder, R., European, CINtec Cytology Study Group, p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study, Cancer Cytopathol, 2011. 119(3): p. 158-66., https://www.ncbi.nlm.nih.gov/pubmed/21442767

339. Stoler, M. H., Wright, T. C., Jr., Sharma, A., Apple, R., Gutekunst, K., Wright, T. L., et.al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study, Am J Clin Pathol, 2011. 135(3): p. 468-75., https://www.ncbi.nlm.nih.gov/pubmed/21350104

340. Szarewski, A., Mesher, D., Cadman, L., Austin, J., Ashdown-Barr, L., Ho, L., et.al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study, J Clin Microbiol, 2012. 50(6): p. 1867-73., https://www.ncbi.nlm.nih.gov/pubmed/22422852

341. Alaghehbandan, R., Fontaine, D., Bentley, J., Escott, N., Ghatage, P., Lear, A., et.al. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology, Diagn Cytopathol, 2013. 41(9): p. 767-75., https://www.ncbi.nlm.nih.gov/pubmed/23341349

342. Oliveira, A., Verdasca, N., Pista, A., Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia, J Med Virol, 2013. 85(7): p. 1235-41., https://www.ncbi.nlm.nih.gov/pubmed/23918542

343. Denise Zielinski, G., Snijders, P. J., Rozendaal, L., Voorhorst, F. J., Runsink, A. P., de Schipper, F. A., et.al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance, J Pathol, 2001. 195(3): p. 300-6., https://www.ncbi.nlm.nih.gov/pubmed/11673826

344. Chen, Hung-Sheng, Su, Tsung-Hsien, Yang, Yang-Cheng, Wang, Tao-Yeuan, Huang, Yu-Wen, Human Papillomavirus Testing (Hybrid Capture Ii) to Detect High-Grade Cervical intraepithelial Neoplasia in Women with Mildly Abnormal Papanicolaou Results, Taiwanese Journal of Obstetrics and Gynecology, 2005. 44(3): p. 252-257., http://dx.doi.org/10.1016/S1028-4559(09)60148-0

345. Cuschieri, K. S., Graham, C., Moore, C., Cubie, H. A., Human Papillomavirus testing for the management of low-grade cervical abnormalities in the UK--Influence of age and testing strategy, J Clin Virol, 2007. 38(1): p. 14-8., https://www.ncbi.nlm.nih.gov/pubmed/17129758

346. You, K., Liang, X., Qin, F., Guo, Y., Geng, L., High-risk human papillomavirus DNA testing and high-grade cervical intraepithelial lesions, Aust N Z J Obstet Gynaecol, 2007. 47(2): p. 141-4., https://www.ncbi.nlm.nih.gov/pubmed/17355305

347. Huang, S., Erickson, B., Tang, N., Mak, W. B., Salituro, J., Robinson, J., et.al. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology, J Clin Virol, 2009. 45 Suppl 1: p. S19-23., https://www.ncbi.nlm.nih.gov/pubmed/19651364

348. Lee, J. K., Kim, M. K., Song, S. H., Hong, J. H., Min, K. J., Kim, J. H., et.al. Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples, Int J Gynecol Cancer, 2009. 19(2): p. 266-72., https://www.ncbi.nlm.nih.gov/pubmed/19396007

349. Edgerton, N., Cohen, C., Siddiqui, M. T., Evaluation of CINtec PLUS(R) testing as an adjunctive test in ASC-US diagnosed SurePath(R) preparations, Diagn Cytopathol, 2013. 41(1): p. 35-40., https://www.ncbi.nlm.nih.gov/pubmed/21710645

350. Wentzensen, N., Schwartz, L., Zuna, R. E., Smith, K., Mathews, C., Gold, M. A., et.al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population, Clin Cancer Res, 2012. 18(15): p. 4154-62., https://www.ncbi.nlm.nih.gov/pubmed/22675168

351. Loghavi, S., Walts, A. E., Bose, S., CINtec(R) PLUS dual immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion, Diagn Cytopathol, 2013. 41(7): p. 582-7., https://www.ncbi.nlm.nih.gov/pubmed/22833355

352. Uijterwaal, M. H., Witte, B. I., Van Kemenade, F. J., Rijkaart, D., Ridder, R., Berkhof, J., et.al. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study, Br J Cancer, 2014. 110(6): p. 1579-86., https://www.ncbi.nlm.nih.gov/pubmed/24518601

353. Bergeron, C., Ikenberg, H., Sideri, M., Denton, K., Bogers, J., Schmidt, D., et.al. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results, Cancer Cytopathol, 2015. 123(6): p. 373-81., https://www.ncbi.nlm.nih.gov/pubmed/25891096

354. Sherman, M. E., Schiffman, M., Cox, J. T., Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study, Group, Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS), J Natl Cancer Inst, 2002. 94(2): p. 102-7., https://www.ncbi.nlm.nih.gov/pubmed/11792748

355. Meyer, J. L., Hanlon, D. W., Andersen, B. T., Rasmussen, O. F., Bisgaard, K., Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results, Cancer, 2007. 111(2): p. 83-92., https://www.ncbi.nlm.nih.gov/pubmed/17334990

356. Castle, P. E., Fetterman, B., Thomas Cox, J., Shaber, R., Poitras, N., Lorey, T., et.al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer, Obstet Gynecol, 2010. 116(1): p. 76-84., https://www.ncbi.nlm.nih.gov/pubmed/20567171

357. Voss, J. S., Kipp, B. R., Campion, M. B., Sokolova, I. A., Henry, M. R., Halling, K. C., et.al. Assessment of fluorescence in situ hybridization and hybrid capture 2 analyses of cervical cytology specimens diagnosed as low grade squamous intraepithelial lesion for the detection of high grade cervical intraepithelial neoplasia, Anal Quant Cytol Histol, 2010. 32(3): p. 121-30., https://www.ncbi.nlm.nih.gov/pubmed/20701064

358. Heider, A., Austin, R. M., Zhao, C., HPV test results stratify risk for histopathologic follow-up findings of high-grade cervical intra-epithelial neoplasia in women with low-grade squamous intra-epithelial lesion Pap results, Acta Cytol, 2011. 55(1): p. 48-53., https://www.ncbi.nlm.nih.gov/pubmed/21135522

359. Levi, A. W., Harigopal, M., Hui, P., Schofield, K., Chhieng, D. C., Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions, Cancer Cytopathol, 2011. 119(4): p. 228-34., https://www.ncbi.nlm.nih.gov/pubmed/21732551

360. Tsoumpou, I., Valasoulis, G., Founta, C., Kyrgiou, M., Nasioutziki, M., Daponte, A., et.al. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study, Gynecol Oncol, 2011. 121(1): p. 49-53., https://www.ncbi.nlm.nih.gov/pubmed/21194734

361. Ziemke, P., Marquardt, K., [Immunocytochemistry of p16(INK4a) and Ki-67 as adjunctive method for routine gynecological cytology of mild and moderate dysplasia], Pathologe, 2013. 34(4): p. 323-8., https://www.ncbi.nlm.nih.gov/pubmed/22752390

362. Waldstrom, M., Christensen, R. K., Ornskov, D., Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion, Cancer Cytopathol, 2013. 121(3): p. 136-45., https://www.ncbi.nlm.nih.gov/pubmed/22987560

363. Massad, L. S., Einstein, M. H., Huh, W. K., Katki, H. A., Kinney, W. K., Schiffman, M., et.al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors, J Low Genit Tract Dis, 2013. 17(5 Suppl 1): p. S1-S27., https://www.ncbi.nlm.nih.gov/pubmed/23519301

364. Bais, A. G., Rebolj, M., Snijders, P. J., de Schipper, F. A., van der Meulen, D. A., Verheijen, R. H., et.al. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines, Int J Cancer, 2005. 116(1): p. 122-9., https://www.ncbi.nlm.nih.gov/pubmed/15751045

365. Berkhof, J., de Bruijne, M. C., Zielinski, G. D., Bulkmans, N. W., Rozendaal, L., Snijders, P. J., et.al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis, Int J Cancer, 2006. 118(7): p. 1759-68., https://www.ncbi.nlm.nih.gov/pubmed/16217759

366. Petry, K. U., Schmidt, D., Scherbring, S., Luyten, A., Reinecke-Luthge, A., Bergeron, C., et.al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology, Gynecol Oncol, 2011. 121(3): p. 505-9., https://www.ncbi.nlm.nih.gov/pubmed/21420158

367. Arbyn, M., Buntinx, F., Van Ranst, M., Paraskevaidis, E., Martin-Hirsch, P., Dillner, J., Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia, J Natl Cancer Inst, 2004. 96(4): p. 280-93., https://www.ncbi.nlm.nih.gov/pubmed/14970277

368. Anderson, MC, Jordan, J, Morse, A, Sharp, F, Stafl, A, Integrated ColposcopyChapman&Hall Medical, 1996.

369. Lee, N. W., Kim, D., Park, J. T., Kim, A., Is the human papillomavirus test in combination with the Papanicolaou test useful for management of patients with diagnoses of atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions?, Arch Pathol Lab Med, 2001. 125(11): p. 1453-7., https://www.ncbi.nlm.nih.gov/pubmed/11698001

370. Pretorius, R. G., Peterson, P., Novak, S., Azizi, F., Sadeghi, M., Lorincz, A. T., Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy, J Reprod Med, 2002. 47(4): p. 290-6., https://www.ncbi.nlm.nih.gov/pubmed/12012880

371. Bornstein, J., Bentley, J., Bosze, P., Girardi, F., Haefner, H., Menton, M., et.al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy, Obstet Gynecol, 2012. 120(1): p. 166-72., https://www.ncbi.nlm.nih.gov/pubmed/22914406

372. Luyten, A., Buttmann-Schweiger, N., Hagemann, I., Scherbring, S., Boehmer, G., Gieseking, F., et.al. Utility and Reproducibility of the International Federation for Cervical Pathology and Colposcopy Classification of Transformation Zones in Daily Practice: A Multicenter Study of the German Colposcopy Network, J Low Genit Tract Dis, 2015. 19(3): p. 185-8., https://www.ncbi.nlm.nih.gov/pubmed/25089552

373. Moss, E. L., Arbyn, M., Dollery, E., Leeson, S., Petry, K. U., Nieminen, P., et.al. European Federation of Colposcopy quality standards Delphi consultation, Eur J Obstet Gynecol Reprod Biol, 2013. 170(1): p. 255-8., https://www.ncbi.nlm.nih.gov/pubmed/23891389

374. Group, Tombola, Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study, BMJ, 2009. 339: p. b2549., https://www.ncbi.nlm.nih.gov/pubmed/19638648

375. Group, Tombola, Biopsy and selective recall compared with immediate large loop excision in management of women with low grade abnormal cervical cytology referred for colposcopy: multicentre randomised controlled trial, BMJ, 2009. 339: p. b2548., https://www.ncbi.nlm.nih.gov/pubmed/19638647

376. Kelly, R. S., Walker, P., Kitchener, H., Moss, S. M., Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities, BJOG, 2012. 119(1): p. 20-5., https://www.ncbi.nlm.nih.gov/pubmed/21624034

377. Jordan, J., Arbyn, M., Martin-Hirsch, P., Schenck, U., Baldauf, J. J., Da Silva, D., et.al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1, Cytopathology, 2008. 19(6): p. 342-54., https://www.ncbi.nlm.nih.gov/pubmed/19040546

378. CONRAD, World Health Organization, Manual for the standardization of colposcopy for the evaluation of vaginal products, 2004., http://whqlibdoc.who.int/hq/2004/WHO_RHR_04.02_eng.pdf

379. Ballagh, S. A., Mauck, C. K., Henry, D., Archer, D. F., Abercrombie, T., Callahan, M. M., et.al. A comparison of techniques to assess cervicovaginal irritation and evaluation of the variability between two observers, Contraception, 2004. 70(3): p. 241-9., https://www.ncbi.nlm.nih.gov/pubmed/15325894

380. Gage, J. C., Hanson, V. W., Abbey, K., Dippery, S., Gardner, S., Kubota, J., et.al. Number of cervical biopsies and sensitivity of colposcopy, Obstet Gynecol, 2006. 108(2): p. 264-72., https://www.ncbi.nlm.nih.gov/pubmed/16880294

381. Massad, L. S., Jeronimo, J., Katki, H. A., Schiffman, M., National Institutes of Health/American Society for, Colposcopy, Cervical Pathology Research, Group, The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia, J Low Genit Tract Dis, 2009. 13(3): p. 137-44., https://www.ncbi.nlm.nih.gov/pubmed/19550210

382. Huh, W. K., Sideri, M., Stoler, M., Zhang, G., Feldman, R., Behrens, C. M., Relevance of random biopsy at the transformation zone when colposcopy is negative, Obstet Gynecol, 2014. 124(4): p. 670-8., https://www.ncbi.nlm.nih.gov/pubmed/25198268

383. Pretorius, R. G., Peterson, P., Azizi, F., Burchette, R. J., Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less, Am J Obstet Gynecol, 2006. 195(5): p. 1260-5., https://www.ncbi.nlm.nih.gov/pubmed/17074547

384. Pretorius, R. G., Belinson, J. L., Burchette, R. J., Hu, S., Zhang, X., Qiao, Y. L., Regardless of skill, performing more biopsies increases the sensitivity of colposcopy, J Low Genit Tract Dis, 2011. 15(3): p. 180-8., https://www.ncbi.nlm.nih.gov/pubmed/21436729

385. Stoler, M. H., Vichnin, M. D., Ferenczy, A., Ferris, D. G., Perez, G., Paavonen, J., et.al. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials, Int J Cancer, 2011. 128(6): p. 1354-62., https://www.ncbi.nlm.nih.gov/pubmed/20506504

386. Wentzensen, N., Walker, J. L., Gold, M. A., Smith, K. M., Zuna, R. E., Mathews, C., et.al. Multiple biopsies and detection of cervical cancer precursors at colposcopy, J Clin Oncol, 2015. 33(1): p. 83-9., https://www.ncbi.nlm.nih.gov/pubmed/25422481

387. Petry, K. U., Luyten, A., Scherbring, S., Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany, Gynecol Oncol, 2013. 128(2): p. 282-7., https://www.ncbi.nlm.nih.gov/pubmed/23088926

388. Luesley, D, Leeson, S, Colposcopy and Programme Management: Guidelines for the NHS Cervical Cancer Screening ProgrammeNHS Cancer Screening Programme, 2004.

389. Hulstaert, F., Arbyn, M., Huybrechts, M., Vinck, I., Puddu, M., Ramaekers, D., Cervical cancer screening and HPVBelgian Health Care Knowledge Centre, 2006.

390. Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., et.al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document, Ann Oncol, 2010. 21(3): p. 448-58., https://www.ncbi.nlm.nih.gov/pubmed/20176693

391. Bundesministerium fuer Gesundheit, Bedeutender Tag fuer die Krebsbekaempfung – Krebsfrueherkennungs- und –registergesetz vom Deutschen Bundestag beschlossen, 2013., http://www.bmg.bund.de/ministerium/presse/pressemitteilungen/2013-01/kfrg-vom-bundestag-beschlossen.html

392. Bundesministerium fuer Gesundheit, Ziel 2a – Weiterentwicklung der Gebaermutterhals-Krebsfrueherkennung, 2012., http://www.bmg.bund.de/praevention/nationaler-krebsplan/was-haben-wir-bisher-erreicht/ziel-2a-weiterentwicklung-der-gebaermutterhals-krebsfrueherkennung.html

393. Gemeinsamer Bundesausschuss, Beschluss des Gemeinsamen Bundesausschusses über eine Beauftragung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen: Erstellung von Einladungsschreiben und Versicherteninformationen zum ZervixkarzinomscreeningGemeinsamer Bundesausschuss,, 2015. 2016:, https://www.g-ba.de/downloads/39-261-2224/2015-03-19_IQWiG-Beauftragung_Einladung-Info-Zervixkarzinom-Sc_WZ.pdf

394. Marquardt, K., Buettner, H. H., Broschewitz, U., Barten, M., Schneider, V., Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause, 2011.

395. Arbyn, M., Simoens, C., Van Oyen, H., Foidart, J. M., Goffin, F., Simon, P., et.al. Analysis of 13 million individual patient records pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000), Prev Med, 2009. 48(5): p. 438-43., https://www.ncbi.nlm.nih.gov/pubmed/19272405

396. Arbyn, M., Fabri, V., Temmerman, M., Simoens, C., Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006), PLoS One, 2014. 9(4): p. e92615., https://www.ncbi.nlm.nih.gov/pubmed/24690620

397. Rousseau, A, Bohet, P, Merlisre, J, Evaluation du dépistage organisé‚ et du dépistage individuel du cancer du col de l'utérus: utilité‚ des données de l'Assurance maladie, Bull Epidemiol Hebdom, 2002. 19: p. 81-4.

398. Klug, S. J., Taylor, K. J., Scheidemann-Wesp, U., Lautz, D., Guther, B., Potthoff, P., et.al. Participation in cervical cancer screening in Germany, Prev Med, 2010. 51(5): p. 431-2., https://www.ncbi.nlm.nih.gov/pubmed/20736032

399. Simou, E., Maniadakis, N., Pallis, A., Foundoulakis, E., Kourlaba, G., Factors associated with the use of pap smear testing in Greece, J Womens Health (Larchmt), 2010. 19(8): p. 1577-85., https://www.ncbi.nlm.nih.gov/pubmed/20626266

400. Oliveira, M., Peleteiro, B., Lunet, N., Cytology use for cervical cancer screening in Portugal: results from the 2005/2006 National Health Survey, Eur J Public Health, 2014. 24(2): p. 253-8., https://www.ncbi.nlm.nih.gov/pubmed/23788013

401. Puig-Tintore, L. M., Castellsague, X., Torne, A., de Sanjose, S., Cortes, J., Roura, E., et.al. Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain, J Low Genit Tract Dis, 2008. 12(2): p. 82-9., https://www.ncbi.nlm.nih.gov/pubmed/18369300

402. Dillner, J., Svensk förening för Obstetrik och Gynekologi (SFOG) 2013Nationellt Kvalitetsregister för Cervixcancerprevention, 2013.

403. Kerek-Bodden, H., Altenhofen, L., Brenner, G., Franke, A., Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002–2004. Eine Untersuchung auf der Basis von Sekundärdaten im Auftrag des Gemeinsamen Bundesausschusses gemäß § 91 SGB VZentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland, Wissenschaftliche Reihe des Zentralinstituts, 2010. 62:

404. Starker, A., Inanspruchnahme von Krebsfrüherkennungsuntersuchungen – Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1), 2013. 56(5-6): p. 868-77., https://www.ncbi.nlm.nih.gov/pubmed/23703508

405. Council of the European Union, Council Recommendation of 2 December 2003 on cancer screening (2003/878/EC), Off J Eur Union, 2003. L327: p. 34-8.

406. Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention, Eur J Cancer, 2000. 36(12): p. 1473-8., https://www.ncbi.nlm.nih.gov/pubmed/10930794

407. Herbert, A., Bergeron, C., Wiener, H., Schenck, U., Klinkhamer, P., Bulten, J., et.al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology, Cytopathology, 2007. 18(4): p. 213-9., https://www.ncbi.nlm.nih.gov/pubmed/17635161

408. Kooperationsgemeinschaft Mammographie, Evaluationsbericht 2011. Zusammenfassung der Ergebnisse des Mammographie-Screening-Programms in Deutschland., 2014.

409. Hakama, M., Trends in the incidence of cervical cancer in the Nordic countries, in Trends in Cancer Incidence, Magnus, K. , Editor. 1982, Hemisphere Publishing Corporation: Washington. p. 279-92.

410. Hakama, M., Miller, AB., Day, NE., Screening for cancer of the uterine cervixWHOIARCUICC and Cancer, UICC Project Group on the Evaluation of Screening Programmes for, Editors. 1986, IARC Sci.Publ.. p. 1-315.

411. Laara, E., Day, N. E., Hakama, M., Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes, Lancet, 1987. 1(8544): p. 1247-9., https://www.ncbi.nlm.nih.gov/pubmed/2884378

412. Sankila, R., Demaret, E., Hakama, M., Lynge, E., Schouten, LJ., Parkin, DM., Evaluation and monitoring of screening programmesOffice for Official publications of the European Communities, 2000.

413. Nygard, J. F., Skare, G. B., Thoresen, S. O., The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer, J Med Screen, 2002. 9(2): p. 86-91., https://www.ncbi.nlm.nih.gov/pubmed/12133929

414. Bjorge, T., Gunbjorud, A. B., Haugen, O. A., Skare, G. B., Trope, C., Thoresen, S. O., Mass screening for cervical cancer in Norway: evaluation of the pilot project, Cancer Causes Control, 1995. 6(6): p. 477-84., https://www.ncbi.nlm.nih.gov/pubmed/8580294

415. Finnish Cancer Registry, Cervical cancer screening, 2014., http://www.cancer.fi/syoparekisteri/en/mass-screening-registry/cervical_cancer_screening/

416. European guidelines for quality assurance in cervical cancer screening. Second edition - SupplementsPublications Office of the European Union, 2015.

417. Leyden, W. A., Manos, M. M., Geiger, A. M., Weinmann, S., Mouchawar, J., Bischoff, K., et.al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process, J Natl Cancer Inst, 2005. 97(9): p. 675-83., https://www.ncbi.nlm.nih.gov/pubmed/15870438

418. Sung, H. Y., Kearney, K. A., Miller, M., Kinney, W., Sawaya, G. F., Hiatt, R. A., Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan, Cancer, 2000. 88(10): p. 2283-2289., http://www.scopus.com/inward/record.url?eid=2-s2.0-0034658425&partnerID=40&md5=f90077fbafc2b300ed3b9cb18c33c4e0

419. Black, M. E., Yamada, J., Mann, V., A systematic literature review of the effectiveness of community-based strategies to increase cervical cancer screening, Can J Public Health, 2002. 93(5): p. 386-93., https://www.ncbi.nlm.nih.gov/pubmed/12353463

420. Camilloni, L., Ferroni, E., Cendales, B. J., Pezzarossi, A., Furnari, G., Borgia, P., et.al. Methods to increase participation in organised screening programs: a systematic review, BMC Public Health, 2013. 13: p. 464., https://www.ncbi.nlm.nih.gov/pubmed/23663511

421. Ferroni, E., Camilloni, L., Jimenez, B., Furnari, G., Borgia, P., Guasticchi, G., et.al. How to increase uptake in oncologic screening: a systematic review of studies comparing population-based screening programs and spontaneous access, Prev Med, 2012. 55(6): p. 587-96., https://www.ncbi.nlm.nih.gov/pubmed/23064024

422. Tseng, D. S., Cox, E., Plane, M. B., Hla, K. M., Efficacy of patient letter reminders on cervical cancer screening: a meta-analysis, J Gen Intern Med, 2001. 16(8): p. 563-8., https://www.ncbi.nlm.nih.gov/pubmed/11556935

423. Stone, E. G., Morton, S. C., Hulscher, M. E., Maglione, M. A., Roth, E. A., Grimshaw, J. M., et.al. Interventions that increase use of adult immunization and cancer screening services: A meta-analysis, Annals of Internal Medicine, 2002. 136(9): p. 641-651., http://www.scopus.com/inward/record.url?eid=2-s2.0-0037035526&partnerID=40&md5=ec2810ff3371760f16dbfdcf67653798

424. Everett, T., Bryant, A., Griffin, M. F., Martin-Hirsch, P. P., Forbes, C. A., Jepson, R. G., Interventions targeted at women to encourage the uptake of cervical screening, Cochrane Database Syst Rev, 2011. (5):CD002834. doi(5): p. CD002834., https://www.ncbi.nlm.nih.gov/pubmed/21563135

425. Burk, W., MARZY-Studie, 2010., http://www.imbei.uni-mainz.de/marzy/

426. Claus, M., Haenselmann, K., Bussas, U., Zeissig, S., Dik, N., Kaiser, M., et.al. Soziale Determinanten der Nichtteilnahme an der MARZY-Studie, Gesundheitswesen, 2010. p. 72-123.

427. Bais, A. G., van Kemenade, F. J., Berkhof, J., Verheijen, R. H., Snijders, P. J., Voorhorst, F., et.al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs, Int J Cancer, 2007. 120(7): p. 1505-10., https://www.ncbi.nlm.nih.gov/pubmed/17205514

428. Gok, M., Heideman, D. A., van Kemenade, F. J., Berkhof, J., Rozendaal, L., Spruyt, J. W., et.al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study, BMJ, 2010. 340: p. c1040-*., https://www.ncbi.nlm.nih.gov/pubmed/20223872

429. Castle, P. E., Rausa, A., Walls, T., Gravitt, P. E., Partridge, E. E., Olivo, V., et.al. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta, Prev Med, 2011. 52(6): p. 452-5., https://www.ncbi.nlm.nih.gov/pubmed/21497619

430. Giorgi Rossi, P., Marsili, L. M., Camilloni, L., Iossa, A., Lattanzi, A., Sani, C., et.al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600), Br J Cancer, 2011. 104(2): p. 248-54., https://www.ncbi.nlm.nih.gov/pubmed/21179038

431. Szarewski, A., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Edwards, R., et.al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial, Br J Cancer, 2011. 104(6): p. 915-920., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065284/

432. Virtanen, A., Nieminen, P., Luostarinen, T., Anttila, A., Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial, Cancer Epidemiol.Biomarkers Prev., 2011. 20(9): p. 1960-1969., https://www.ncbi.nlm.nih.gov/pubmed/21752985

433. Gok, M., van Kemenade, F. J., Heideman, D. A., Berkhof, J., Rozendaal, L., Spruyt, J. W., et.al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program, Int J Cancer, 2012. 130(5): p. 1128-35., https://www.ncbi.nlm.nih.gov/pubmed/21484793

434. Darlin, L., Borgfeldt, C., Forslund, O., Henic, E., Hortlund, M., Dillner, J., et.al. Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening, J.Clin.Virol., 2013., http://www.sciencedirect.com/science/article/pii/S1386653213002618

435. Logan, L., McIlfatrick, S., Exploring women's knowledge, experiences and perceptions of cervical cancer screening in an area of social deprivation, Eur J Cancer Care (Engl), 2011. 20(6): p. 720-7., https://www.ncbi.nlm.nih.gov/pubmed/21521388

436. Huynh, J., Howard, M., Lytwyn, A., Self-collection for vaginal human papillomavirus testing: systematic review of studies asking women their perceptions, J.Low Genit.Tract.Dis., 2010. 14(4): p. 356-362.

437. Mitchell, S., Ogilvie, G., Steinberg, M., Sekikubo, M., Biryabarema, C., Money, D., Assessing women's willingness to collect their own cervical samples for HPV testing as part of the ASPIRE cervical cancer screening project in Uganda, Int J Gynaecol Obstet, 2011. 114(2): p. 111-115.

438. Wikstrom, I., Stenvall, H., Wilander, E., Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening, Acta Obstet Gynecol Scand, 2007. 86(6): p. 720-725., https://www.ncbi.nlm.nih.gov/pubmed/17520406

439. Wikstroem, I., Lindell, M., Sanner, K., Wilander, E., Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: A randomised study, British Journal of Cancer, 2011. 105(3): p. 337-339., https://www.ncbi.nlm.nih.gov/pubmed/21730977

440. Leniz, J., Barriga, M. I., Lagos, M., Ibanez, C., Puschel, K., Ferreccio, C., HPV vaginal self-sampling among women non-adherent to Papanicolaou screening in Chile, Salud Publica Mex., 2013. 55(2): p. 162-169., https://www.ncbi.nlm.nih.gov/pubmed/23546407

441. Dannecker, C., Siebert, U., Thaler, C. J., Kiermeir, D., Hepp, H., Hillemanns, P., Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics, Ann Oncol, 2004. 15(6): p. 863-9., https://www.ncbi.nlm.nih.gov/pubmed/15151941

442. Morrison, E. A., Goldberg, G. L., Hagan, R. J., Kadish, A. S., Burk, R. D., Self-administered home cervicovaginal lavage: a novel tool for the clinical-epidemiologic investigation of genital human papillomavirus infections, Am J Obstet Gynecol, 1992. 167(1): p. 104-7., https://www.ncbi.nlm.nih.gov/pubmed/1332474

443. Hillemanns, P., Kimmig, R., Huttemann, U., Dannecker, C., Thaler, C. J., Screening for cervical neoplasia by self-assessment for human papillomavirus DNA, Lancet, 1999. 354(9194): p. 1970., https://www.ncbi.nlm.nih.gov/pubmed/10622304

444. Sellors, J. W., Lorincz, A. T., Mahony, J. B., Mielzynska, I., Lytwyn, A., Roth, P., et.al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions, CMAJ, 2000. 163(5): p. 513-8., https://www.ncbi.nlm.nih.gov/pubmed/11006761

445. Wright Jr, T. C., Denny, L., Kuhn, L., Pollack, A., Lorincz, A., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association, 2000. 283(1): p. 81-86., https://www.ncbi.nlm.nih.gov/pubmed/10632284

446. Belinson, J., Qiao, Y. L., Pretorius, R., Zhang, W. H., Elson, P., Li, L., et.al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia, Gynecol Oncol, 2001. 83(2): p. 439-44., https://www.ncbi.nlm.nih.gov/pubmed/11606114

447. Lorenzato, F. R., Singer, A., Ho, L., Santos, L. C., Batista Rde, L., Lubambo, T. M., et.al. Human papillomavirus detection for cervical cancer prevention with polymerase chain reaction in self-collected samples, Am J Obstet Gynecol, 2002. 186(5): p. 962-8., https://www.ncbi.nlm.nih.gov/pubmed/12015522

448. Nobbenhuis, M. A. E., Helmerhorst, T. J. M., Van den Brule, A. J. C., Rozendaal, L., Jaspars, L. H., Voorhorst, F. J., et.al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women, Journal of Clinical Pathology, 2002. 55(6): p. 435-439., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769675/

449. Garcia, F., Barker, B., Santos, C., Brown, E. M., Nuno, T., Giuliano, A., et.al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus, Obstet Gynecol, 2003. 102(2): p. 266-72., https://www.ncbi.nlm.nih.gov/pubmed/12907098

450. Salmeron, J., Lazcano-Ponce, E., Lorincz, A., Hernandez, M., Hernandez, P., Leyva, A., et.al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico, Cancer Causes and Control, 2003. 14(6): p. 505-512., https://www.ncbi.nlm.nih.gov/pubmed/12948281

451. Brink, A. A., Meijer, C. J., Wiegerinck, M. A., Nieboer, T. E., Kruitwagen, R. F., van Kemenade, F., et.al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush, J Clin Microbiol, 2006. 44(7): p. 2518-23., https://www.ncbi.nlm.nih.gov/pubmed/16825374

452. Daponte, A., Pournaras, S., Mademtzis, I., Hadjichristodoulou, C., Kostopoulou, E., Maniatis, A. N., et.al. Evaluation of HPV 16 PCR detection in self- compared with clinician-collected samples in women referred for colposcopy, Gynecol Oncol, 2006. 103(2): p. 463-6., https://www.ncbi.nlm.nih.gov/pubmed/16626791

453. Girianelli, V. R., Thuler, L. C., Szklo, M., Donato, A., Zardo, L. M., Lozana, J. A., et.al. Comparison of human papillomavirus DNA tests, liquid-based cytology and conventional cytology for the early detection of cervix uteri cancer, Eur J Cancer Prev, 2006. 15(6): p. 504-10., https://www.ncbi.nlm.nih.gov/pubmed/17106330

454. Holanda Jr, F., Castelo, A., Veras, T. M. C. W., de Almeida, F. M. L., Lins, M. Z., Dores, G. B., Primary screening for cervical cancer through self sampling, International Journal of Gynecology and Obstetrics, 2006. 95(2): p. 179-184.

455. Seo, S. S., Song, Y. S., Kim, J. W., Park, N. H., Kang, S. B., Lee, H. P., Good correlation of HPV DNA test between self-collected vaginal and clinician-collected cervical samples by the oligonucleotide microarray, Gynecologic Oncology, 2006. 102(1): p. 67-73.

456. Szarewski, A., Cadman, L., Mallett, S., Austin, J., Londesborough, P., Waller, J., et.al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting, J Med Screen, 2007. 14(1): p. 34-42., https://www.ncbi.nlm.nih.gov/pubmed/17362570

457. Qiao, Y. L., Sellors, J. W., Eder, P. S., Bao, Y. P., Lim, J. M., Zhao, F. H., et.al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China, Lancet Oncol, 2008. 9(10): p. 929-36., https://www.ncbi.nlm.nih.gov/pubmed/18805733

458. Bhatla, N., Dar, L., Patro, A. R., Kumar, P., Kriplani, A., Gulati, A., et.al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?, Cancer Epidemiology, 2009. 33(6): p. 446-450., https://www.ncbi.nlm.nih.gov/pubmed/19931499

459. Balasubramanian, A., Kulasingam, S. L., Baer, A., Hughes, J. P., Myers, E. R., Mao, C., et.al. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples, J Low Genit Tract Dis, 2010. 14(3): p. 185-95., https://www.ncbi.nlm.nih.gov/pubmed/20592553

460. Gustavsson, I., Sanner, K., Lindell, M., Strand, A., Olovsson, M., Wikstrom, I., et.al. Type-specific detection of high-risk human papillomavirus (HPV) in self-sampled cervicovaginal cells applied to FTA elute cartridge, J Clin Virol, 2011. 51(4): p. 255-8., https://www.ncbi.nlm.nih.gov/pubmed/21632283

461. Taylor, S., Wang, C., Wright, T. C., Denny, L., Kuhn, L., A comparison of human papillomavirus testing of clinician-collected and self-collected samples during follow-up after screen-and-treat, Int J Cancer, 2011. 129(4): p. 879-86., https://www.ncbi.nlm.nih.gov/pubmed/20957631

462. Twu, N. F., Yen, M. S., Lau, H. Y., Chen, Y. J., Yu, B. K., Lin, C. Y., Type-specific human papillomavirus DNA testing with the genotyping array: a comparison of cervical and vaginal sampling, Eur J Obstet Gynecol Reprod Biol, 2011. 156(1): p. 96-100., https://www.ncbi.nlm.nih.gov/pubmed/21288625

463. Belinson, J. L., Du, H., Yang, B., Wu, R., Belinson, S. E., Qu, X., et.al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing, Int J Cancer, 2012. 130(8): p. 1855-60., https://www.ncbi.nlm.nih.gov/pubmed/21630255

464. Dijkstra, M. G., Heideman, D. A., van Kemenade, F. J., Hogewoning, K. J., Hesselink, A. T., Verkuijten, M. C., et.al. Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN, J Clin Virol, 2012. 54(2): p. 147-51., https://www.ncbi.nlm.nih.gov/pubmed/22445557

465. Longatto-Filho, A., Naud, P., Derchain, S. F., Roteli-Martins, C., Tatti, S., Hammes, L. S., et.al. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology, Virchows Arch, 2012. 460(6): p. 577-85., https://www.ncbi.nlm.nih.gov/pubmed/22562132

466. Van Baars, R., Bosgraaf, R. P., Ter Harmsel, B. W. A., Melchers, W. J. G., Quint, W. G. V., Bekkers, R. L. M., Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women, Journal of Clinical Microbiology, 2012. 50(12): p. 3937-3943., https://www.ncbi.nlm.nih.gov/pubmed/23015677

467. Zhao, F. H., Lewkowitz, A. K., Chen, F., Lin, M. J., Hu, S. Y., Zhang, X., et.al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method, Journal of the National Cancer Institute, 2012. 104(3): p. 178-188., https://www.ncbi.nlm.nih.gov/pubmed/22271765

468. Geraets, D. T., van Baars, R., Alonso, I., Ordi, J., Torne, A., Melchers, W. J. G., et.al. Clinical evaluation of high-risk HPV detection on self-samples using the indicating FTA-elute solid-carrier cartridge, Journal of Clinical Virology, 2013. 57(2): p. 125-129., https://www.ncbi.nlm.nih.gov/pubmed/23518442

469. Guan, Y., Gravitt, P. E., Howard, R., Eby, Y. J., Wang, S., Li, B., et.al. Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens, Journal of Virological Methods, 2013. 189(1): p. 167-171., https://www.ncbi.nlm.nih.gov/pubmed/23370404

470. Jentschke, M., Lange, V., Soergel, P., Hillemanns, P., Enzyme-linked immunosorbent assay for p16INK4a - A new triage test for the detection of cervical intraepithelial neoplasia?, Acta Obstetricia et Gynecologica Scandinavica, 2013. 92(2): p. 160-164., https://www.ncbi.nlm.nih.gov/pubmed/23072258

471. Jentschke, M., Soergel, P., Hillemanns, P., Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples, J Virol Methods, 2013. 193(1): p. 131-4., https://www.ncbi.nlm.nih.gov/pubmed/23707925

472. Arbyn, M., Verdoodt, F., Snijders, P. J., Verhoef, V. M., Suonio, E., Dillner, L., et.al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis, Lancet Oncol, 2014. 15(2): p. 172-83., https://www.ncbi.nlm.nih.gov/pubmed/24433684

473. World Health Organization, WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization.World Health Organization,, 2014., www.who.int/reproductivehealth/publications/cancers/treatment_CIN_2-3/en/index.html

474. Colposcopy and programme management Guidelines for the NHS Cervical Screening ProgrammeNHS Cancer Screening Programmes, 2010. 2016: p. NHSCSP Publication No 20., https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/436873/nhscsp20.pdf

475. AQUA, Konisation AbschlussberichtInstitut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen GmbH, 2010., https://www.sqg.de/sqg/upload/CONTENT/Neue-Verfahren/Konisation/Abschlussbericht_Konisation.pdf

476. Martin-Hirsch, P. P., Paraskevaidis, E., Bryant, A., Dickinson, H. O., Surgery for cervical intraepithelial neoplasia, Cochrane Database Syst Rev, 2013. 12(12): p. CD001318., https://www.ncbi.nlm.nih.gov/pubmed/24302546

477. Vercellino, G. F., Erdemoglu, E., Chiantera, V., Malak, A. H., Vasiljeva, K., Drechsler, I., et.al. A multicentric randomized study comparing two techniques of magnification assisted loop excision of high-grade cervical intraepithelial neoplasia: video exoscopy and colposcopy, Arch Gynecol Obstet, 2014. 289(6): p. 1301-7., https://www.ncbi.nlm.nih.gov/pubmed/24370959

478. Schlecht, N. F., Platt, R. W., Duarte-Franco, E., Costa, M. C., Sobrinho, J. P., Prado, J. C., et.al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia, J Natl Cancer Inst, 2003. 95(17): p. 1336-43., https://www.ncbi.nlm.nih.gov/pubmed/12953088

479. Nobbenhuis, M. A., Helmerhorst, T. J., van den Brule, A. J., Rozendaal, L., Voorhorst, F. J., Bezemer, P. D., et.al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear, Lancet, 2001. 358(9295): p. 1782-3., https://www.ncbi.nlm.nih.gov/pubmed/11734239

480. Moscicki, A. B., Shiboski, S., Hills, N. K., Powell, K. J., Jay, N., Hanson, E. N., et.al. Regression of low-grade squamous intra-epithelial lesions in young women, Lancet, 2004. 364(9446): p. 1678-83., https://www.ncbi.nlm.nih.gov/pubmed/15530628

481. Cox, J. T., Schiffman, M., Solomon, D., Group, Ascus-Lsil Triage Study, Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy, Am J Obstet Gynecol, 2003. 188(6): p. 1406-12., https://www.ncbi.nlm.nih.gov/pubmed/12824970

482. Konisation - AbschlussberichtAQUA - Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen GmbH, Sektorenübergreifende Qualitätssicherung im Gesundheitswesen, 2010. 2016:, https://www.sqg.de/sqg/upload/CONTENT/Neue-Verfahren/Konisation/Abschlussbericht_Konisation.pdf

483. Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J. C., Castle, P. E., Human papillomavirus testing in the prevention of cervical cancer, J Natl Cancer Inst, 2011. 103(5): p. 368-83., https://www.ncbi.nlm.nih.gov/pubmed/21282563

484. Ghaem-Maghami, S., Sagi, S., Majeed, G., Soutter, W. P., Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis, Lancet Oncol, 2007. 8(11): p. 985-93., https://www.ncbi.nlm.nih.gov/pubmed/17928267

485. Baldauf, J. J., Dreyfus, M., Ritter, J., Meyer, P., Philippe, E., Risk of cervical stenosis after large loop excision or laser conization, Obstet Gynecol, 1996. 88(6): p. 933-8., https://www.ncbi.nlm.nih.gov/pubmed/8942830

486. Kyrgiou, M., Koliopoulos, G., Martin-Hirsch, P., Arbyn, M., Prendiville, W., Paraskevaidis, E., Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis, Lancet, 2006. 367(9509): p. 489-98., https://www.ncbi.nlm.nih.gov/pubmed/16473126

487. Bruinsma, F. J., Quinn, M. A., The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis, BJOG, 2011. 118(9): p. 1031-41., https://www.ncbi.nlm.nih.gov/pubmed/21449928

488. Khalid, S., Dimitriou, E., Conroy, R., Paraskevaidis, E., Kyrgiou, M., Harrity, C., et.al. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity, BJOG, 2012. 119(6): p. 685-91., https://www.ncbi.nlm.nih.gov/pubmed/22329499

489. Simoens, C., Goffin, F., Simon, P., Barlow, P., Antoine, J., Foidart, J. M., et.al. Adverse obstetrical outcomes after treatment of precancerous cervical lesions: a Belgian multicentre study, BJOG, 2012. 119(10): p. 1247-55., https://www.ncbi.nlm.nih.gov/pubmed/22804838

490. Al-Halal, H., Kezouh, A., Abenhaim, H. A., Incidence and obstetrical outcomes of cervical intraepithelial neoplasia and cervical cancer in pregnancy: a population-based study on 8.8 million births, Arch Gynecol Obstet, 2013. 287(2): p. 245-50., https://www.ncbi.nlm.nih.gov/pubmed/23053308

491. Pereg, D., Koren, G., Lishner, M., Cancer in pregnancy: gaps, challenges and solutions, Cancer Treat Rev, 2008. 34(4): p. 302-12., https://www.ncbi.nlm.nih.gov/pubmed/18291591

492. Michael, C. W., Esfahani, F. M., Pregnancy-related changes: a retrospective review of 278 cervical smears, Diagn Cytopathol, 1997. 17(2): p. 99-107., https://www.ncbi.nlm.nih.gov/pubmed/9258616

493. Economos, K., Perez Veridiano, N., Delke, I., Collado, M. L., Tancer, M. L., Abnormal cervical cytology in pregnancy: a 17-year experience, Obstet Gynecol, 1993. 81(6): p. 915-8., https://www.ncbi.nlm.nih.gov/pubmed/8497355

494. Fader, A. N., Alward, E. K., Niederhauser, A., Chirico, C., Lesnock, J. L., Zwiesler, D. J., et.al. Cervical dysplasia in pregnancy: a multi-institutional evaluation, Am J Obstet Gynecol, 2010. 203(2): p. 113 e1-6., https://www.ncbi.nlm.nih.gov/pubmed/20522409

495. Kaplan, K. J., Dainty, L. A., Dolinsky, B., Rose, G. S., Carlson, J., McHale, M., et.al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy, Cancer, 2004. 102(4): p. 228-32., https://www.ncbi.nlm.nih.gov/pubmed/15368314

496. Ahdoot, D., Van Nostrand, K. M., Nguyen, N. J., Tewari, D. S., Kurasaki, T., DiSaia, P. J., et.al. The effect of route of delivery on regression of abnormal cervical cytologic findings in the postpartum period, Am J Obstet Gynecol, 1998. 178(6): p. 1116-20., https://www.ncbi.nlm.nih.gov/pubmed/9662288

497. Coppolillo, E. F., HM, D. E. Ruda Vega, Brizuela, J., Eliseth, M. C., Barata, A., Perazzi, B. E., High-grade cervical neoplasia during pregnancy: diagnosis, management and postpartum findings, Acta Obstet Gynecol Scand, 2013. 92(3): p. 293-7., https://www.ncbi.nlm.nih.gov/pubmed/22880637

498. Paraskevaidis, E., Koliopoulos, G., Kalantaridou, S., Pappa, L., Navrozoglou, I., Zikopoulos, K., et.al. Management and evolution of cervical intraepithelial neoplasia during pregnancy and postpartum, Eur J Obstet Gynecol Reprod Biol, 2002. 104(1): p. 67-9., https://www.ncbi.nlm.nih.gov/pubmed/12128266

499. Yost, N. P., Santoso, J. T., McIntire, D. D., Iliya, F. A., Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions, Obstet Gynecol, 1999. 93(3): p. 359-62., https://www.ncbi.nlm.nih.gov/pubmed/10074979

500. McIntyre-Seltman, K., Lesnock, J. L., Cervical cancer screening in pregnancy, Obstet Gynecol Clin North Am, 2008. 35(4): p. 645-58; x., https://www.ncbi.nlm.nih.gov/pubmed/19061823

501. Arbyn, M., Kyrgiou, M., Simoens, C., Raifu, A. O., Koliopoulos, G., Martin-Hirsch, P., et.al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis, BMJ, 2008. 337: p. a1284., https://www.ncbi.nlm.nih.gov/pubmed/18801868

502. Jin, G., LanLan, Z., Li, C., Dan, Z., Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis, Arch Gynecol Obstet, 2014. 289(1): p. 85-99., https://www.ncbi.nlm.nih.gov/pubmed/23843155

503. Liu, Y., Qiu, H. F., Tang, Y., Chen, J., Lv, J., Pregnancy outcome after the treatment of loop electrosurgical excision procedure or cold-knife conization for cervical intraepithelial neoplasia, Gynecol Obstet Invest, 2014. 77(4): p. 240-4., https://www.ncbi.nlm.nih.gov/pubmed/24752130

504. Kyrgiou, M., Arbyn, M., Martin-Hirsch, P., Paraskevaidis, E., Increased risk of preterm birth after treatment for CIN, BMJ, 2012. 345: p. e5847., https://www.ncbi.nlm.nih.gov/pubmed/22951549

505. Noehr, B., Jensen, A., Frederiksen, K., Tabor, A., Kjaer, S. K., Depth of cervical cone removed by loop electrosurgical excision procedure and subsequent risk of spontaneous preterm delivery, Obstet Gynecol, 2009. 114(6): p. 1232-8., https://www.ncbi.nlm.nih.gov/pubmed/19935024

506. Reilly, R., Paranjothy, S., Beer, H., Brooks, C. J., Fielder, H. M., Lyons, R. A., Birth outcomes following treatment for precancerous changes to the cervix: a population-based record linkage study, BJOG, 2012. 119(2): p. 236-44., https://www.ncbi.nlm.nih.gov/pubmed/21790951

507. Alonso, I., Torne, A., Puig-Tintore, L. M., Esteve, R., Quinto, L., Campo, E., et.al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3, Gynecol Oncol, 2006. 103(2): p. 631-6., https://www.ncbi.nlm.nih.gov/pubmed/16780934

508. Melnikow, J., McGahan, C., Sawaya, G. F., Ehlen, T., Coldman, A., Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study, J Natl Cancer Inst, 2009. 101(10): p. 721-8., https://www.ncbi.nlm.nih.gov/pubmed/19436026

509. Strander, B., Hallgren, J., Sparen, P., Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality, BMJ, 2014. 348(348): p. f7361., https://www.ncbi.nlm.nih.gov/pubmed/24423603

510. Trope, A., Jonassen, C. M., Sjoborg, K. D., Nygard, M., Dahl, F. A., Alfsen, G. C., et.al. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia, Gynecol Oncol, 2011. 123(2): p. 257-62., https://www.ncbi.nlm.nih.gov/pubmed/21839500

511. Ryu, A., Nam, K., Kwak, J., Kim, J., Jeon, S., Early human papillomavirus testing predicts residual/recurrent disease after LEEP, J Gynecol Oncol, 2012. 23(4): p. 217-25., https://www.ncbi.nlm.nih.gov/pubmed/23094124

512. Verguts, J., Bronselaer, B., Donders, G., Arbyn, M., Van Eldere, J., Drijkoningen, M., et.al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation, BJOG : an international journal of obstetrics and gynaecology, 2006. 113(11): p. 1303-7., https://www.ncbi.nlm.nih.gov/pubmed/16978225

513. Kang, W. D., Oh, M. J., Kim, S. M., Nam, J. H., Park, C. S., Choi, H. S., Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure, Am J Obstet Gynecol, 2010. 203(1): p. 72 e1-6., https://www.ncbi.nlm.nih.gov/pubmed/20417477

514. Cecchini, Silvia, Carozzi, Francesca, Confortini, Massimo, Zappa, Marco, Ciatto, Stefano, Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure, Tumori, 2004. 90(2): p. 225-8., https://www.ncbi.nlm.nih.gov/pubmed/15237586

515. Ang, C., Mukhopadhyay, A., Burnley, C., Faulkner, K., Cross, P., Martin-Hirsch, P., et.al. Histological recurrence and depth of loop treatment of the cervix in women of reproductive age: incomplete excision versus adverse pregnancy outcome, BJOG, 2011. 118(6): p. 685-92., https://www.ncbi.nlm.nih.gov/pubmed/21429068

516. Flannelly, G., Bolger, B., Fawzi, H., De Lopes, A. B., Monaghan, J. M., Follow up after LLETZ: could schedules be modified according to risk of recurrence?, BJOG : an international journal of obstetrics and gynaecology, 2001. 108(10): p. 1025-30., https://www.ncbi.nlm.nih.gov/pubmed/11702832

517. Prato, B., Ghelardi, A., Gadducci, A., Marchetti, I., Di Cristofano, C., Di Coscio, G., et.al. Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions, Int J Gynecol Cancer, 2008. 18(1): p. 90-4., https://www.ncbi.nlm.nih.gov/pubmed/17506849

518. Castle, P. E., Schiffman, M., Herrero, R., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., et.al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica, J Infect Dis, 2005. 191(11): p. 1808-16., https://www.ncbi.nlm.nih.gov/pubmed/15871112

519. Aerssens, A., Claeys, P., Garcia, A., Sturtewagen, Y., Velasquez, R., Vanden Broeck, D., et.al. Natural history and clearance of HPV after treatment of precancerous cervical lesions, Histopathology, 2008. 52(3): p. 381-6., https://www.ncbi.nlm.nih.gov/pubmed/18269589

520. Sarian, L. O., Derchain, S. F., Pitta Dda, R., Morais, S. S., Rabelo-Santos, S. H., Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ), J Clin Virol, 2004. 31(4): p. 270-4., https://www.ncbi.nlm.nih.gov/pubmed/15494268

521. Strander, B., Andersson-Ellstrom, A., Milsom, I., Sparen, P., Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study, BMJ, 2007. 335(7629): p. 1077., https://www.ncbi.nlm.nih.gov/pubmed/17959735

522. Jeong, N. H., Lee, N. W., Kim, H. J., Kim, T., Lee, K. W., High-risk human papillomavirus testing for monitoring patients treated for high-grade cervical intraepithelial neoplasia, J Obstet Gynaecol Res, 2009. 35(4): p. 706-11., https://www.ncbi.nlm.nih.gov/pubmed/19751331

523. Moscicki, A. B., Schiffman, M., Burchell, A., Albero, G., Giuliano, A. R., Goodman, M. T., et.al. Updating the natural history of human papillomavirus and anogenital cancers, Vaccine, 2012. 30 Suppl 5: p. F24-33., https://www.ncbi.nlm.nih.gov/pubmed/23199964

524. Paraskevaidis, E., Arbyn, M., Sotiriadis, A., Diakomanolis, E., Martin-Hirsch, P., Koliopoulos, G., et.al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature, Cancer Treat Rev, 2004. 30(2): p. 205-11., https://www.ncbi.nlm.nih.gov/pubmed/15023438

525. Lacey, C. J., Therapy for genital human papillomavirus-related disease, J Clin Virol, 2005. 32 Suppl 1: p. S82-90., https://www.ncbi.nlm.nih.gov/pubmed/15753016

526. Stern, P. L., van der Burg, S. H., Hampson, I. N., Broker, T. R., Fiander, A., Lacey, C. J., et.al. Therapy of human papillomavirus-related disease, Vaccine, 2012. 30 Suppl 5: p. F71-82., https://www.ncbi.nlm.nih.gov/pubmed/23199967

527. Soutter, W. P., Sasieni, P., Panoskaltsis, T., J., Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia, Int, 2005. 118(8 SRC - GoogleScholar): p. 2048-2055.

528. Kalliala, I., Anttila, A., Pukkala, E., Nieminen, P., Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study, BMJ, 2005. 331(7526): p. 1183-5., https://www.ncbi.nlm.nih.gov/pubmed/16293840

529. Arbyn, M., Kyrgiou, M., Gondry, J., Petry, K. U., Paraskevaidis, E., Long term outcomes for women treated for cervical precancer, BMJ, 2014. 348: p. f7700., https://www.ncbi.nlm.nih.gov/pubmed/24423750

530. Harbord, R. M., Whiting, P., Metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression, Stata Journal, 2009. 9(2): p. 211-229.

531. Takwoingi, Y., Deeks, JJ., MetaDAS: A SAS macro for meta-analysis of diagnostic accuracy studies. Quick reference and worked example. Version 1.3., 2010., http://srdta.cochrane.org/.

532. Diagnostic Test Accuracy Working Group, Handbook for diagnostic test accuracy reviews, 2011., http://srdta.cochrane.org/handbook-dta-reviews

533. DerSimonian, R., Laird, N., Meta-analysis in clinical trials, Control Clin Trials, 1986. 7(3): p. 177-88., https://www.ncbi.nlm.nih.gov/pubmed/3802833

534. Torne, A., Fuste, P., Rodriguez-Carunchio, L., Alonso, I., del Pino, M., Nonell, R., et.al. Intraoperative post-conisation human papillomavirus testing for early detection of treatment failure in patients with cervical intraepithelial neoplasia: a pilot study, BJOG, 2013. 120(4): p. 392-9., https://www.ncbi.nlm.nih.gov/pubmed/23189989

535. Chua, K. L., Hjerpe, A., Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri, Gynecologic oncology, 1997. 66(1): p. 108-13., https://www.ncbi.nlm.nih.gov/pubmed/9234930

536. Heymans, J., Benoy, I. H., Poppe, W., Depuydt, C. E., Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation, Int J Cancer, 2011. 129(4): p. 903-9., https://www.ncbi.nlm.nih.gov/pubmed/21064091

537. Zielinski, G. Denise, Rozendaal, Lawrence, Voorhorst, Feja J., Berkhof, Johannus, Snijders, Peter J. F., Risse, Elle J. K., et.al. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3, Gynecologic oncology, 2003. 91(1): p. 67-73., https://www.ncbi.nlm.nih.gov/pubmed/14529664

538. Sarian, L. O., Derchain, S. F., Andrade, L. A., Tambascia, J., Morais, S. S., Syrjanen, K. J., HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia, Gynecol Oncol, 2004. 94(1): p. 181-6., https://www.ncbi.nlm.nih.gov/pubmed/15262139

539. Kreimer, Aimee R., Guido, Richard S., Solomon, Diane, Schiffman, Mark, Wacholder, Sholom, Jeronimo, Jose, et.al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006. 15(5): p. 908-14., https://www.ncbi.nlm.nih.gov/pubmed/16702369

540. Smart, O. C., Sykes, P., Macnab, H., Jennings, L., Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions, Aust N Z J Obstet Gynaecol, 2010. 50(2): p. 164-7., https://www.ncbi.nlm.nih.gov/pubmed/20522074

541. Nobbenhuis, M. A., Meijer, C. J., van den Brule, A. J., Rozendaal, L., Voorhorst, F. J., Risse, E. K., et.al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia, Br J Cancer, 2001. 84(6): p. 796-801., https://www.ncbi.nlm.nih.gov/pubmed/11259094

542. Fambrini, M., Penna, C., Pieralli, A., Bussani, C., Fallani, M. G., Andersson, K. L., et.al. PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia, Gynecol Oncol, 2008. 109(1): p. 59-64., https://www.ncbi.nlm.nih.gov/pubmed/18255129

543. Aerssens, A., Claeys, P., Beerens, E., Garcia, A., Weyers, S., Van Renterghem, L., et.al. Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia, Cytopathology, 2009. 20(1): p. 27-35., https://www.ncbi.nlm.nih.gov/pubmed/18510550

544. Bais, Aagje G., Eijkemans, Marinus J. C., Rebolj, Mateja, Snijders, Peter J. F., Verheijen, Rene H. M., van Ballegooijen, Marjolein, et.al. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease, International journal of cancer. Journal international du cancer, 2009. 124(4): p. 889-95., https://www.ncbi.nlm.nih.gov/pubmed/19048594

545. Arbyn, M., Paraskevaidis, E., Martin-Hirsch, P., Prendiville, W., Dillner, J., Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence, Gynecol Oncol, 2005. 99(3 Suppl 1): p. S7-11., https://www.ncbi.nlm.nih.gov/pubmed/16154623

546. Zielinski, G. D., Bais, A. G., Helmerhorst, T. J., Verheijen, R. H., de Schipper, F. A., Snijders, P. J., et.al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis, Obstet Gynecol Surv, 2004. 59(7): p. 543-53., https://www.ncbi.nlm.nih.gov/pubmed/15199273

547. Chan, B. K., Melnikow, J., Slee, C. A., Arellanes, R., Sawaya, G. F., Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review, Am J Obstet Gynecol, 2009. 200(4): p. 422 e1-9., https://www.ncbi.nlm.nih.gov/pubmed/19167697

548. Kocken, M., Uijterwaal, M. H., de Vries, A. L., Berkhof, J., Ket, J. C., Helmerhorst, T. J., et.al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis, Gynecol Oncol, 2012. 125(2): p. 500-7., https://www.ncbi.nlm.nih.gov/pubmed/22266548

549. Strander, Bjoern, Ryd, Walter, Wallin, Keng-Ling, Waerleby, Bengt, Zheng, Biying, Milsom, Ian, et.al. Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?, European journal of cancer (Oxford, England : 1990), 2007. 43(12): p. 1849-55., https://www.ncbi.nlm.nih.gov/pubmed/17614272

550. Kocken, M., Helmerhorst, T. J., Berkhof, J., Louwers, J. A., Nobbenhuis, M. A., Bais, A. G., et.al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study, Lancet Oncol, 2011. 12(5): p. 441-50., https://www.ncbi.nlm.nih.gov/pubmed/21530398

551. Houfflin Debarge, V., Collinet, P., Vinatier, D., Ego, A., Dewilde, A., Boman, F., et.al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions, Gynecol Oncol, 2003. 90(3): p. 587-92., https://www.ncbi.nlm.nih.gov/pubmed/13678729

552. Chao, A., Lin, C. T., Hsueh, S., Chou, H. H., Chang, T. C., Chen, M. Y., et.al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization, Am J Obstet Gynecol, 2004. 190(4): p. 1046-51., https://www.ncbi.nlm.nih.gov/pubmed/15118639

553. Leguevaque, P., Motton, S., Decharme, A., Soule-Tholy, M., Escourrou, G., Hoff, J., Predictors of recurrence in high-grade cervical lesions and a plan of management, Eur J Surg Oncol, 2010. 36(11): p. 1073-9., https://www.ncbi.nlm.nih.gov/pubmed/20870375

554. Persson, Maria, Brismar Wendel, Sophia, Ljungblad, Linda, Johansson, Bo, Weiderpass, Elisabete, Andersson, Sonia, High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia, Oncology reports, 2012. 28(1): p. 346-52., https://www.ncbi.nlm.nih.gov/pubmed/22484610

555. Tinelli, A., Guido, M., Zizza, A., Pellegrino, M., Greco, M., Vergara, D., et.al. The mRNA-HPV test utilization in the follow up of HPV related cervical lesions, Curr Pharm Des, 2013. 19(8): p. 1458-65., https://www.ncbi.nlm.nih.gov/pubmed/23016779

556. Brismar, S., Johansson, B., Borjesson, M., Arbyn, M., Andersson, S., Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping, Am J Obstet Gynecol, 2009. 201(1): p. 17 e1-8., https://www.ncbi.nlm.nih.gov/pubmed/19344881

557. Boulet, G. A., Micalessi, I. M., Horvath, C. A., Benoy, I. H., Depuydt, C. E., Bogers, J. J., Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification, J Clin Microbiol, 2010. 48(7): p. 2524-9., https://www.ncbi.nlm.nih.gov/pubmed/20463156

558. Horneber, Markus, Bueschel, Gerd, Dennert, Gabriele, Less, Danuta, Ritter, Erik, Zwahlen, Marcel, How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis, Integrative cancer therapies, 2012. 11(3): p. 187-203., https://www.ncbi.nlm.nih.gov/pubmed/22019489

559. Uzzo, R. G., Brown, J. G., Horwitz, E. M., Hanlon, A., Mazzoni, S., Konski, A., et.al. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer, BJU international, 2004. 93(7): p. 955-60., https://www.ncbi.nlm.nih.gov/pubmed/15142142

560. Beebe-Dimmer, Jennifer L., Wood, David P., Gruber, Stephen B., Douglas, Julie A., Bonner, Joseph D., Mohai, Caroline, et.al. Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study, Urology, 2004. 63(2): p. 282-7., https://www.ncbi.nlm.nih.gov/pubmed/14972472

561. Muenstedt, Karsten, El-Safadi, Samer, Brueck, Friedel, Zygmunt, Marek, Hackethal, Andreas, Tinneberg, Hans-Rudolf, Can iridology detect susceptibility to cancer? A prospective case-controlled study, Journal of alternative and complementary medicine (New York, N.Y.), 2005. 11(3): p. 515-9., https://www.ncbi.nlm.nih.gov/pubmed/15992238

562. Braun, S., Reimer, D., Strobl, I., Wieland, U., Wiesbauer, P., Muller-Holzner, E., et.al. Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report, J Med Case Rep, 2011. 5: p. 316., https://www.ncbi.nlm.nih.gov/pubmed/21767367

563. Swanick, S., Windstar-Hamlin, K., Zwickey, H., An alternative treatment for cervical intraepithelial neoplasia II, III, Integr Cancer Ther, 2009. 8(2): p. 164-7., https://www.ncbi.nlm.nih.gov/pubmed/19679625

564. Goodman, M. T., Kiviat, N., McDuffie, K., Hankin, J. H., Hernandez, B., Wilkens, L. R., et.al. The association of plasma micronutrients with the risk of cervical dysplasia in Hawaii, Cancer Epidemiol Biomarkers Prev, 1998. 7(6): p. 537-44., https://www.ncbi.nlm.nih.gov/pubmed/9641499

565. Hwang, J. H., Kim, M. K., Lee, J. K., Dietary supplements reduce the risk of cervical intraepithelial neoplasia, Int J Gynecol Cancer, 2010. 20(3): p. 398-403., https://www.ncbi.nlm.nih.gov/pubmed/20375804

566. Mackerras, D., Irwig, L., Simpson, J. M., Weisberg, E., Cardona, M., Webster, F., et.al. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities, Br J Cancer, 1999. 79(9-10): p. 1448-53., https://www.ncbi.nlm.nih.gov/pubmed/10188889

567. Keefe, K. A., Schell, M. J., Brewer, C., McHale, M., Brewster, W., Chapman, J. A., et.al. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2001. 10(10): p. 1029-35., https://www.ncbi.nlm.nih.gov/pubmed/11588128

568. Alvarez, Ronald D., Conner, Michael G., Weiss, Heidi, Klug, Patricia M., Niwas, Santosh, Manne, Upender, et.al. The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2003. 12(2): p. 114-9., https://www.ncbi.nlm.nih.gov/pubmed/12582020

569. Kwanbunjan, K., Saengkar, P., Cheeramakara, C., Tangjitgamol, S., Chitcharoenrung, K., Vitamin B12 status of Thai women with neoplasia of the cervix uteri, Southeast Asian J Trop Med Public Health, 2006. 37 Suppl 3: p. 178-83., https://www.ncbi.nlm.nih.gov/pubmed/17547077

570. Schulte-Uebbing, C., Schlett, S., Craiut, I., Antal, L., Olah, H., Chronical cervical infections and dysplasia (CIN I, CIN II): Vaginal vitamin D (high dose) treatment: A new effective method?, Dermatoendocrinol, 2014. 6(1): p. e27791., https://www.ncbi.nlm.nih.gov/pubmed/24605180

571. Hosono, S., Matsuo, K., Kajiyama, H., Hirose, K., Suzuki, T., Kawase, T., et.al. Association between dietary calcium and vitamin D intake and cervical carcinogenesis among Japanese women, European journal of clinical nutrition, 2010. 64(4): p. 400-9., https://www.ncbi.nlm.nih.gov/pubmed/20197786

572. Butterworth, C. E., Jr., Hatch, K. D., Gore, H., Mueller, H., Krumdieck, C. L., Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives, Am J Clin Nutr, 1982. 35(1): p. 73-82., https://www.ncbi.nlm.nih.gov/pubmed/7064879

573. Butterworth, C. E., Jr., Hatch, K. D., Soong, S. J., Cole, P., Tamura, T., Sauberlich, H. E., et.al. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial, Am J Obstet Gynecol, 1992. 166(3): p. 803-9., https://www.ncbi.nlm.nih.gov/pubmed/1312773

574. Piyathilake, Chandrika J., Macaluso, Maurizio, Celedonio, Jorge E., Badiga, Suguna, Bell, Walter C., Grizzle, William E., Mandatory fortification with folic acid in the United States appears to have adverse effects on histone methylation in women with pre-cancer but not in women free of pre-cancer, International journal of women's health, 2010. 1: p. 131-7., https://www.ncbi.nlm.nih.gov/pubmed/21072283

575. Ahn, W. S., Yoo, J., Huh, S. W., Kim, C. K., Lee, J. M., Namkoong, S. E., et.al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions, Eur J Cancer Prev, 2003. 12(5): p. 383-90., https://www.ncbi.nlm.nih.gov/pubmed/14512803

576. Garcia, F. A., Cornelison, T., Nuno, T., Greenspan, D. L., Byron, J. W., Hsu, C. H., et.al. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia, Gynecol Oncol, 2014. 132(2): p. 377-82., https://www.ncbi.nlm.nih.gov/pubmed/24388920

577. Metzner, Ralf, Schneider, Heike Ursula, Breuer, Uwe, Schroeder, Walter Heinz, Imaging nutrient distributions in plant tissue using time-of-flight secondary ion mass spectrometry and scanning electron microscopy, Plant physiology, 2008. 147(4): p. 1774-87., https://www.ncbi.nlm.nih.gov/pubmed/18567833

578. Del Priore, G., Gudipudi, D. K., Montemarano, N., Restivo, A. M., Malanowska-Stega, J., Arslan, A. A., Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia, Gynecol Oncol, 2010. 116(3): p. 464-7., https://www.ncbi.nlm.nih.gov/pubmed/19939441

579. Kim, S. Y., Kim, J. W., Ko, Y. S., Koo, J. E., Chung, H. Y., Lee-Kim, Y. C., Changes in lipid peroxidation and antioxidant trace elements in serum of women with cervical intraepithelial neoplasia and invasive cancer, Nutr Cancer, 2003. 47(2): p. 126-30., https://www.ncbi.nlm.nih.gov/pubmed/15087263

580. Imhof, M., Lipovac, M., Kurz, Ch, Barta, J., Verhoeven, H. C., Huber, J. C., Propolis solution for the treatment of chronic vaginitis, Int J Gynaecol Obstet, 2005. 89(2): p. 127-32., https://www.ncbi.nlm.nih.gov/pubmed/15847875

581. Iljazovic, Ermina, Ljuca, Dzenita, Sahimpasic, Ademir, Avdic, Silvija, Efficacy in treatment of cervical HRHPV infection by combination of beta interferon, and herbal therapy in woman with different cervical lesions, Bosnian journal of basic medical sciences / Udruzenje basicnih mediciniskih znanosti = Association of Basic Medical Sciences, 2006. 6(4): p. 79-84., https://www.ncbi.nlm.nih.gov/pubmed/17177657

582. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau, Langversion 3.0, 2012., http://leitlinienprogramm-onkologie.de/Mammakarzinom.67.0.html

583. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Langversion-Konsultationsfassung 0.1, 2014., http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html

584. Steinbach, Kerstin, Oorschot, Birgitt van, Anselm, Rainer, Leppert, Karena, Schweitzer, Susanne, Hausmann, Christopher, et.al. Patienten als Partner: Wer soll entscheiden?, Dtsch Arztebl International, 2004. 1(41): p. -3-., http://www.aerzteblatt.de/int/article.asp?id=43750

585. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73(3): p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/18952394

586. Albert, U. S., Schulz, K. D., Alt, D., Beck, V., Doherty, J., Holsteg, K., et.al. A guideline for guidelines - Methodological report and use of the guideline women's information, Zentralblatt Fur Gynakologie, 2003. 125(12): p. 484-493., , to, ISI>://WOS:000187639300003

587. O'Connor, A. M., Rostom, A., Fiset, V., Tetroe, J., Entwistle, V., Llewellyn-Thomas, H., et.al. Decision aids for patients facing health treatment or screening decisions: systematic review, BMJ, 1999. 319(7212): p. 731-4., https://www.ncbi.nlm.nih.gov/pubmed/10487995

588. Leitlinie des OSP Stuttgart zur Diagnostik und Therapie des VulvakarzinomsOnkologischer Schwerpunkt Stuttgart, 2012., www.osp-stuttgart.de/leitlinien/Leitlinien/Leitlinie_Vulva_Ca.pdf

589. Zuerner, P, Beckmann, I A, Die blauen Ratgeber: Patienten und Ärzte als Partner, 2012.

590. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Prävention von Hautkrebs, Langversion-Konsultationsfassung 0.1, 2014., http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html

591. BMG, „Inanspruchnahme Krebsfrüherkennung“, Handlungsfeld 1 „Weiterentwicklung der Krebsfrüherkennung“ des Nationalen Krebsplans, 2010.

592. Seedat, J., Marcus, U., Smolinski, F., Fehrmann, S., Petschelt, J., Epidemiologisches Bulletin Nr. 34, Aktuelle Daten und Informationen zu Infektionskrankheiten und Public HealthRobert-Koch Institut, 2014., http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/Ausgaben/34_14.pdf?__blob=publicationFile

593. Gardasil Fachinformation (Zusammenfassung der Merkmale des Arzneimittels), 2014., www.zervita.de/share/Informationen/FI-Gardasil_06-2014_v2.pdf

594. EMA, Gardasil -EMEA/H/C/000703, 2014., http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp&mid=WC0b01ac058001d124

595. EMA, Cervarix EMEA/H/C/000721, 2013., http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124

596. a, Impfung gegen Humane Papillomviren, a., http://www.zervita.de/

597. Frederiksen, M. E., Njor, S., Lynge, E., Rebolj, M., Psychological effects of diagnosis and treatment of cervical intraepithelial neoplasia: a systematic review, Sex Transm Infect, 2015. 91(4): p. 248-56., https://www.ncbi.nlm.nih.gov/pubmed/25512668

598. Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., Gray, A., Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study, BMJ, 2004. 328(7451): p. 1293., https://www.ncbi.nlm.nih.gov/pubmed/15166066

599. McCaffery, K., Waller, J., Forrest, S., Cadman, L., Szarewski, A., Wardle, J., Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact, BJOG, 2004. 111(12): p. 1437-43., https://www.ncbi.nlm.nih.gov/pubmed/15663132

600. McCaffery, K., Waller, J., Nazroo, J., Wardle, J., Social and psychological impact of HPV testing in cervical screening: a qualitative study, Sex Transm Infect, 2006. 82(2): p. 169-74., https://www.ncbi.nlm.nih.gov/pubmed/16581749

601. Johnson, C. Y., Sharp, L., Cotton, S. C., Harris, C. A., Gray, N. M., Little, J., et.al. Human papillomavirus infection and anxiety: analyses in women with low-grade cervical cytological abnormalities unaware of their infection status, PLoS One, 2011. 6(6): p. e21046., https://www.ncbi.nlm.nih.gov/pubmed/21698168

602. Korfage, I. J., Essink-Bot, M. L., Westenberg, S. M., Helmerhorst, T., Habbema, J. D., van Ballegooijen, M., How distressing is referral to colposcopy in cervical cancer screening?: a prospective quality of life study, Gynecol Oncol, 2014. 132(1): p. 142-8., https://www.ncbi.nlm.nih.gov/pubmed/24219984

603. Sharp, L., Cotton, S., Carsin, A. E., Gray, N., Thornton, A., Cruickshank, M., et.al. Factors associated with psychological distress following colposcopy among women with low-grade abnormal cervical cytology: a prospective study within the Trial Of Management of Borderline and Other Low-grade Abnormal smears (TOMBOLA), Psychooncology, 2013. 22(2): p. 368-80., https://www.ncbi.nlm.nih.gov/pubmed/22162138

604. Kwan, T. T., Cheung, A. N., Lo, S. S., Lee, P. W., Tam, K. F., Chan, K. K., et.al. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study, Acta Obstet Gynecol Scand, 2011. 90(5): p. 445-51., https://www.ncbi.nlm.nih.gov/pubmed/21306349

605. Siebert, U., Alagoz, O., Bayoumi, A.M., Jahn, B., Owens, D.K., Cohen, D.J., et.al. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -3, Medical Decision Making, 2012. 32(5): p. 690-700., pdf

606. Siebert, U., When should decision-analytic modeling be used in the economic evaluation of health care? [Editorial], European Journal of Health Economics, 2003. 4(3): p. 143-150., pdf, C:\!Fulltext\Siebert\Siebert_2003_Eur, J, Health, Econom_When, should, DA, modeling, be, used, in, econom, eval.pdf

607. Siebert, U., Transparente Entscheidungen in Public Health mittels systematischer Entscheidungsanalyse, in Public Health. Gesundheit und Gesundheitswesen, Schwartz, F. W.Walter, U.Siegrist, J.Kolip, P.Leidl, R.Dierks, M.-L.Busse, R. and Schneider, N., Editors. 2012, Urban & Fischer in Elsevier: München. p. 517-535., pdf

608. Lorenz, W., Ollenschlaeger, G., Geraedts, M., Gerlach, F., Gandjour, A., Helou, A., et.al. Das Leitlinien-Manual: Entwicklung und Implementierung von Leitlinien in der Medizin, Zeitschrift für ärztliche Fortbildung und Qualitätssicherung, 2001. 95(Suppl I): p. 1-84.

609. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Erarbeitung von Leitlinien für Diagnostik und Therapie - Methodische Empfehlungen ("Leitlinie für Leitlinien", Stand Dez. 2004).Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), 2004., http://www.awmf.org/fileadmin/user_upload/Leitlinien/Werkzeuge/Publikationen/methoden.pdf

610. Leidl, R., von der Schulenburg, J.M., Wasem, J., Ansätze und Methoden der ökonomischen Evaluation - eine internationale Perspektive Health Technology AssessmentNomos, 1999.

611. IQWiG, Allgemeine Methoden (Version 4.2)Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2015.

612. Sroczynski, G., Siebert, U., Evidence Report: Decision analysis to evaluate benefits, harms and cost-effectiveness of different cervical cancer screening strategies to inform the S3 clinical guideline "Prevention of Cervical Cancer" in the context of the German health care systemUMIT - University for Health Sciences, Medical Informatics and Technology, 2015.

613. Siebert, U., Muth, C., Sroczynski, G., Velasco-Garrido, M., Gerhardus, A., Gibis, B., Dünnschichtpräparationen und computergestützte Untersuchung von Zervixabstrichen im Rahmen der Krebsfrüherkennung – Medizinische Effektivität, gesundheitsökonomische Evaluation und systematische Entscheidungsanalyse. Schriftenreihe Health Technology Assessment Bd. 35Asgard, 2004. 35: p. 444., pdf

614. Siebert, U., Sroczynski, G., Hillemanns, P., Engel, J., Stabenow, R., Stegmaier, C., et.al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany, Eur J Public Health, 2006. 16(2): p. 185-92., https://www.ncbi.nlm.nih.gov/pubmed/16469759

615. Sroczynski, G., Schnell-Inderst, P., Muehlberger, N., Lang, K., Aidelsburger, P., Wasem, J., et.al. Entscheidungsanalytische Modellierung zur Evaluation der Langzeit-Effektivität und Kosten-Effektivität des Einsatzes der HPV-DNA-Diagnostik im Rahmen der Zervixkarzinomfrüherkennung in Deutschland. Schriftenreihe Health Technology Assessment Bd. 98Deutsches Institut für Medizinische Dokumentation und Information (DIMDI), Bundesministerium für Gesundheit (BMG), 2010. p. 1-127., pdf

616. Sroczynski, G., Schnell-Inderst, P., Muhlberger, N., Lang, K., Aidelsburger, P., Wasem, J., et.al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis, Eur J Cancer, 2011. 47(11): p. 1633-46., https://www.ncbi.nlm.nih.gov/pubmed/21482103

617. Caro, J. J., Briggs, A.H., Siebert, U., Kuntz, K.M., on behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force, Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -1, Medical Decision Making, 2012. 32(5): p. 667-77., pdf

618. Drummond, M. F., Schwartz, J. S., Jonsson, B., Luce, B. R., Neumann, P. J., Siebert, U., et.al. Key principles for the improved conduct of health technology assessments for resource allocation decisions, Int J Technol Assess Health Care, 2008. 24(3): p. 244-58; discussion 362-8., https://www.ncbi.nlm.nih.gov/pubmed/18601792

619. Drummond, M., Schwartz, J. S., Jonsson, B., Luce, B., Neumann, P., Siebert, U., et.al. Response from the authors of "Key principles for the improved conduct of health technology assessments for resource allocation decisions", Int J Technol Assess Health Care, 2008. 24(3): p. 367-8., pdf, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18601809

620. IQWiG, Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Nutzen und Kosten (Version 1.0)Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2009.

621. Griesser, H., Breinl, H., Jordan, B., Gynäkologische Dysplasien werden klar zugeordnet, Dtsch Arztebl, 2014. 111(15): p. A-640 / B-550 / C-530.

622. Griesser, H., Marquardt, K., Jordan, B., Kueppers, V., Gieseking, F., Kuehn, W., Zervix-Zytologie. Das Prozedere bei auffälligen Befunden. Kommentar zur Münchner Nomenklatur III, Frauenarzt, 2015. 56: p. 10-13.

623. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF, Leitlinienprogramm Onkologie: S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Langversion (Version 1.0, September 2014), AWMF-Registernummer 032/033OL, 2014. 2015:, http://leitlinienprogramm-onkologie.de/uploads/tx_sbdownloader/LL_Zervixkarzinom_Langversion_1.0.pdf

624. Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J., Poljak, M., Ogilvie, G., et.al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer, Vaccine, 2012. 30 Suppl 5: p. F88-99., https://www.ncbi.nlm.nih.gov/pubmed/23199969

625. Cuzick, J., Clavel, C., Petry, K. U., Meijer, C. J., Hoyer, H., Ratnam, S., et.al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening, Int J Cancer, 2006. 119(5): p. 1095-101., https://www.ncbi.nlm.nih.gov/pubmed/16586444

626. McCrory, D.C., Matchar, D.B., Evaluation of cervical cytology - systematic reviewAgency for Health Care Research and Quality (AHRQ), 1999.

627. Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., et.al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review, Ann Intern Med, 2000. 132(10): p. 810-9., https://www.ncbi.nlm.nih.gov/pubmed/10819705

628. Birnie, R., Wolff, R., Hilmer, D., et al., Evidence Review for the S3 guideline “Prevention of Cervical Cancer”, 2014.

629. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C., Cost-Effectiveness in Health and MedicineOxford University Press Inc., 1996.

630. Manual Qualitätsindikatoren. Manual für Autoren.Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), 2009. äzq Schriftenreihe: 36:, http://www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe36.pdf

631. Schwarzer, R., Rochau, U., Saverno, K., Jahn, B., Bornschein, B., Muehlberger, N., et.al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents, J Comp Eff Res, 2015. 4(5): p. 485-504., https://www.ncbi.nlm.nih.gov/pubmed/26490020

632. Gramsch, E., Hoppe, JD., Jonitz, G., Koehler, A., Ollenschlaeger, G et al., Kompendium Q-M-A. Qualitätsmanagement in der ambulanten VersorgungDt. Ärzte-Verl., 2008.

633. Jenson, E. G., Baker, M., Paydarfar, J. A., Gosselin, B. J., Li, Z., Black, C. C., MCM2/TOP2A (ProExC) immunohistochemistry as a predictive marker in head and neck mucosal biopsies, Pathol Res Pract, 2014. 210(6): p. 346-50., https://www.ncbi.nlm.nih.gov/pubmed/24630889

634. Cuzick, J., Bergeron, C., von Knebel Doeberitz, M., Gravitt, P., Jeronimo, J., Lorincz, A. T., et.al. New technologies and procedures for cervical cancer screening, Vaccine, 2012. 30 Suppl 5: p. F107-16., https://www.ncbi.nlm.nih.gov/pubmed/23199953

635. Poljak, M., Cuzick, J., Kocjan, B. J., Iftner, T., Dillner, J., Arbyn, M., Nucleic acid tests for the detection of alpha human papillomaviruses, Vaccine, 2012. 30 Suppl 5: p. F100-6., https://www.ncbi.nlm.nih.gov/pubmed/23199952

636. Luhn, P., Wentzensen, N., HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease, Curr Obstet Gynecol Rep, 2013. 2(2): p. 76-85., https://www.ncbi.nlm.nih.gov/pubmed/23705102

637. Isaacson Wechsler, E., Wang, Q., Roberts, I., Pagliarulo, E., Jackson, D., Untersperger, C., et.al. Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression, J Virol, 2012. 86(11): p. 6358-64., https://www.ncbi.nlm.nih.gov/pubmed/22457518

638. a, Zentrum für Krebsregisterdaten am Robert Koch-Institut, 2014.

639. Vercellino, G. F., Chiantera, V., Gassmann, J., Erdemoglu, E., Drechsler, I., Frangini, S., et.al. Prospective Comparison of Loop Excision under Colposcopic Guidance versus Vitom Guidance, Geburtshilfe Frauenheilkd, 2012. 72(10): p. 945-948., https://www.ncbi.nlm.nih.gov/pubmed/25258454